Targeted therapeutic agents and uses thereof

Chimeric proteins with modified signaling agents and targeting moieties like PD-1 and PD-L1 address the limitations of conventional cancer therapies by providing targeted cancer treatment with reduced side effects and enhanced immune response.

JP2024164840APending Publication Date: 2024-11-27ORIONIS BIOSCIENCES INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024133824
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-10-24
Filing Date
2024-08-09
Publication Date
2024-11-27

AI Technical Summary

Technical Problem

Conventional cancer therapies like chemotherapy and radiation lack cell specificity, and immunotherapies such as checkpoint blockade therapy fail in most patients, often causing significant side effects and narrowing the therapeutic window.

Method used

Development of chimeric proteins with targeted therapeutic agents, including modified signaling agents like human interferon-α2, TNF-α, and IL-1β, linked to targeting moieties like PD-1 and PD-L1, to enhance immune response while minimizing side effects.

Benefits of technology

The chimeric proteins provide targeted therapy for cancer with reduced side effects, improving treatment efficacy by enhancing the immune response against cancer cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164840000001_ABST
    Figure 2024164840000001_ABST
Patent Text Reader

Abstract

To provide improved immunotherapeutic agents that can provide targeted therapy against cancers while causing minimal side effects.SOLUTION: In a chimeric protein, a targeting moiety and a modified signaling agent are connected by linkers. The targeting moiety has a recognition domain that binds to a checkpoint protein selected from programmed cell death protein 1 (PD-1), PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). The modified signaling agent is selected from one or more of an interleukin, an interferon and a tumor necrosis factor.SELECTED DRAWING: Figure 5
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is incorporated herein by reference in its entirety, in accordance with U.S. Provisional Patent Application Nos. 62 / 291,769, filed February 5, 2016; 62 / 335,880, filed May 13, 2016; 62 / 411,805, filed October 24, 2016; 62 / 291,772, filed February 5, 2016; 62 / 291,774, filed February 5, 2016; and 62 / 291,775, filed May 13, 2016. The patent claims the benefit of No. 2 / 335,965, filed February 5, 2016; No. 62 / 291,776, filed May 13, 2016; No. 62 / 335,968, filed May 13, 2016; No. 62 / 335,979, filed May 13, 2016; No. 62 / 336,030, filed May 13, 2016, No. 62 / 353,607, filed June 23, 2016; and No. 62 / 291,779, filed February 5, 2016.

[0002] Field The present invention relates, in part, to targeted therapeutic agents and their use in treating diseases such as cancer.

[0003] Description of electronically submitted text files The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: Computer Readable Format Copy of Sequence Listing (Filename: ORN-021PC_Sequence_listing; Recorded on: February 1, 2017; File Size: 231 KB). [Background technology]

[0004] In contrast to conventional cancer therapies, such as chemotherapy and radiation, immunotherapy offers the advantage of cell specificity to cancer cells. In particular, immunotherapy directly targets cancer cells by inducing, enhancing or suppressing the patient's own immune response. As such, methods for enhancing the efficacy of immune-based therapy can be clinically beneficial. However, despite impressive patient responses to agents that target immune co-stimulatory and co-inhibitory molecules, including the clinical trials that led to the approval of YERVOY, KEYTRUDA, and OPDIVO, immunotherapies such as checkpoint inhibitor therapy still fail in the vast majority of patients. Furthermore, many immunotherapies are complicated by side effects that significantly narrow the patient's therapeutic window for treatment and make the patient more susceptible to other diseases.

[0005] Thus, there remains a need for improved immunotherapeutic agents that can provide targeted therapy for cancer while causing minimal side effects. Summary of the Invention

[0006] In some aspects, the invention relates to chimeric proteins having one targeting moiety that has a recognition domain (e.g., an antigen recognition domain, including various antibody formats, including, without limitation, single domain antibodies) that specifically binds to a target (e.g., an antigen, receptor) of interest. In various embodiments, the targeting moiety has a recognition domain that binds to a checkpoint protein selected from programmed cell death protein 1 (PD-1), PD-1 ligand 1 (PD-L1; also known as B7-H1 and CD274), and PD-1 ligand 2 (PD-L2; also known as B7-DC and CD273).

[0007] In various embodiments, the chimeric protein further comprises a modified (e.g., mutated) signaling agent (e.g., an immunomodulatory agent). In various embodiments, the modified (e.g., mutated) signaling agent has one or more modifications (e.g., mutations) that provide improved safety when compared to an unmodified (e.g., wild-type) signaling agent. In various embodiments, the modified signaling agent is selected from one or more of an interleukin, an interferon, and a tumor necrosis factor. In one embodiment, the modified signaling agent is human interferon-α2. In another embodiment, the modified signaling agent is human TNF-α. In a further embodiment, the modified signaling agent is human IL-1β.

[0008] In some embodiments, the targeting moiety and the modified (e.g., mutated) signaling agent are linked by one or more linkers.

[0009] In various embodiments, the chimeric proteins of the present invention find use in the treatment of a variety of diseases or disorders, such as cancer, infections, immune disorders, and autoimmune diseases, and the present invention encompasses a variety of therapeutic methods. [Brief description of the drawings]

[0010] [Figure 1] Figure 1 shows that C57BL / 6 mice were inoculated subcutaneously (50μl) with 6x105 B16mCD20cl1 melanoma tumor cells. When tumors reached a size of ±10mm2 as measured by caliper, perilesional treatment with 120μg of anti-PD-L1 VHH (120μl) or anti-PD-L1 VHH fusion to human IFNalpha, Q124R mutant was initiated. The curves are in the same order (top to bottom) as in the figure legend identifying the treatment type (e.g. PBS is the top curve, anti-PD-L1 is the middle curve, and the bottom curve is anti-PD-L1 VHH fusion to human IFNalpha, Q124R mutant). [Diagram 2]Figure 2 shows the efficacy data and corresponding safety data from Figure 1 in panels A-G. In panel A, mouse weights are shown for all treatment types. In panels B-G, all data are presented as three sets of histograms, which are from left to right: PBS, anti-PD-L1 VHH, and fusion of anti-PD-L1 VHH to human IFN alpha, Q124R. Shown are white blood cell count ("wbc") and lymphocyte count ("ly") (Panel B), neutrophil count ("ne") and monocyte count ("mo") (Panel C); red blood cell count ("rbc") and hemoglobin ("hb") (Panel D); hematocrit ("hct"), mean corpuscular volume ("mcv"), mean corpuscular hemoglobin ("mch"), mean corpuscular hemoglobin concentration ("mchc") (Panel E); enucleated (pitted) red blood cells ("pit") (Panel F); and mean platelet volume ("mpv") (Panel G). [Diagram 3] Figure 3 shows the effect of serial dilutions of anti-human PD-1 VHH, anti-human PD-L1 VHH, anti-mouse PD-L1 VHH or irrelevant VHH when tested in a PD1 / PD-L1 plate binding assay. The mean ± standard deviation of triplicate determinations is plotted. Curves from top to bottom with 10,000 points are: anti-mouse PD-L1 VHH, irrelevant VHH, anti-human PD-1 VHH, and anti-human PD-L1 VHH. [Figure 4] Figure 4 shows an experiment in which MDA-MB-321 cells were stimulated with serial dilutions of anti-PD-L1 / attenuated IFN chimeras and stained for phospho-STAT1. Data are plotted as mean fluorescence intensity (MFI). The top curve is anti-human PD-L1 VHH / human IFN R149A. [Diagram 5] Figure 5 shows a human dendritic cell pSTAT1 signaling assay. The chimeras studied were anti-human PD-L1 VHH / human IFN R149A and anti-human PD-L1 VHH / human IFN R33A / E120R. Two doses of agent were studied: 100ng / ml and 500ng / ml. PBS was the control and data are expressed as fold change in the percentage of pSTAT1+ dendritic cells (data are the average of triplicate data sets). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] The present invention provides chimeric proteins comprising a signaling agent having a therapeutically beneficial mutation and a targeting moiety that targets the signaling agent to a site where therapeutic action is required (e.g., tumor cells) or appropriate (e.g., immune cells). The present invention provides pharmaceutical compositions comprising the chimeric proteins and their use in treating a variety of diseases. Administration of the chimeric proteins and pharmaceutical compositions of the present invention achieves significantly reduced side effects compared to wild-type signaling agents.

[0012] targeting part In various embodiments, the chimeric protein has one targeting moiety directed against an immune checkpoint protein, which in various embodiments is selected from programmed cell death protein 1 (PD-1), PD-1 ligand 1 (PD-L1; also known as B7-H1 and CD274), and PD-1 ligand 2 (PD-L2; also known as B7-DC and CD273).

[0013] In various embodiments, the targeting moiety of the chimeric protein of the present invention is a protein-based agent capable of specific binding, such as an antibody or a derivative thereof. In one embodiment, the targeting moiety comprises an antibody. In various embodiments, the antibody is a full-length multimeric protein comprising two heavy chains and two light chains. Each heavy chain comprises one variable region (e.g., V H ) and at least three constant regions (e.g., CH1, CH2, and CH3), and each light chain comprises one variable region (V L ) and one constant region (C L). The variable regions determine the specificity of the antibody. Each variable region contains three hypervariable regions, also known as complementarity determining regions (CDRs), flanked by four relatively conserved framework regions (FRs). The three CDRs, designated CDR1, CDR2, and CDR3, contribute to the antibody binding specificity. In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody.

[0014] In some embodiments, the targeting moiety comprises an antibody derivative or form. In some embodiments, the targeting portion of the chimeric protein is a targeting moiety as described in U.S. patents or patent publications US 7,417,130, US 2004 / 132094, US 5,831,012, US 2004 / 023334, US 7,250,297, US 6,818,418, US 2004 / 209243, US 7,838,629, US 7,186,524, US 6,004,746, US 5,475,096, US 2004 / 146938, US 2004 / 157209, US 6,994,982, US 6,794,144, US 2010 / 239633, US 7,803,907, US 2010 / 119446, and / or US 7,166,697, including single domain antibodies, recombinant heavy chain only antibodies (VHH), single chain antibodies (scFv), shark heavy chain only antibodies (VNAR), microproteins (cysteine ​​knot proteins, knottins), DARPins; tetranectins; affibodies; transbodies; anticalins; adnectins; affilins; microbodies; peptide aptamers; alterases; plastic antibodies; phylomers; stradobodies; maxibodies; shrimp bodies; finomers; armadillo repeat proteins, Kunitz domains, avimers, atrimers, probodies, immunobodies, triomabs, troibodies; pepbodies; vaccibodies; unibodies; affimers; duobodies, Fv, Fab, Fab', F(ab')2, peptidomimetic molecules, or synthetic molecules. See also Storz MAbs. 2011 May-Jun; 3(3): 310-317.

[0015] In one embodiment, the targeting moiety comprises a single domain antibody, e.g., VHH from organisms that produce VHH antibodies, such as camelids, sharks, or engineered VHHs. VHHs are antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally occurring heavy chain antibodies. VHH technology is based on fully functional antibodies from camelids that lack light chains. These heavy chain antibodies contain a single variable domain (VHH) and two constant domains (CH2 and CH3). VHHs are commercially available under the trade name NANOBODIES.

[0016] In various embodiments, the chimeric protein of the present invention has one targeting moiety directed against PD-1. PD-1 is expressed on the majority of tumor-infiltrating lymphocytes derived from many different tumor types. For example, PD-1 is highly expressed on CD4+ and CD8+ T cells. PD-1 is also expressed on other activated non-T lymphocytes, including B cells and natural killer (NK) cells. In some embodiments, the chimeric protein comprises a targeting moiety directed against PD-1 and a modified IFN-α comprising one or more mutations as described herein (e.g., human IFN-α2 mutations as described herein). In some embodiments, the chimeric protein comprises: a targeting moiety directed against PD-1 and a modified TNF-α comprising one or more mutations as described herein. In some embodiments, the chimeric protein comprises: a targeting moiety directed against PD-1 and a modified IL-1β comprising one or more mutations as described herein.

[0017] In various embodiments, the chimeric proteins of the invention have a targeting moiety directed against PD-1. In some embodiments, the chimeric proteins have a targeting moiety that selectively binds a PD-1 polypeptide. In some embodiments, the chimeric proteins comprise an antibody, an antibody derivative or form, a peptide or polypeptide, or a fusion protein that selectively binds a PD-1 polypeptide.

[0018] In one embodiment, the targeting moiety comprises the anti-PD-1 antibody pembrolizumab (also known as MK-3475, KEYTRUDA), or a fragment thereof. Pembrolizumab and other humanized PD-1 antibodies are disclosed in Hamid et al. (2013) New England Journal of Medicine 369 (2): 134-44, US 8,354,509, and WO 2009 / 114335, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, pembrolizumab or an antigen-binding fragment thereof for use in the methods provided herein comprises: QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNF NEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEG NVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 1) and / or a heavy chain comprising the amino acid sequence of: EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLES GVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:2) and a light chain comprising the amino acid sequence of

[0019] In one embodiment, the targeting moiety comprises the anti-PD-1 antibody, nivolumab (also known as BMS-936558, MDX-1106, ONO-4538, OPDIVO), or a fragment thereof. Nivolumab (clone 5C4) and other human monoclonal antibodies that specifically bind to PD-1 are disclosed in US 8,008,449 and WO 2006 / 121168, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, nivolumab or an antigen-binding fragment thereof is: QVQLVESGGG VVQPGRSLRL DCKASGITFS NSGMHWVRQA PGKGLEWVAV IWYDGSKRYY ADSVKGRFTI SRDNSKNTLF LQMNSLRAED TAVYYCATND DYWGQGTLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPSQEE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW QEGNVFSCSV MHEALHNHYT QKSLSLSLGK (SEQ ID NO:3) and / or a heavy chain comprising the amino acid sequence of: EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ SSNWPRTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC (SEQ ID NO:4) and a light chain comprising the amino acid sequence of

[0020] In one embodiment, the targeting moiety comprises the anti-PD-1 antibody pidilizumab (also known as CT-011, hBAT or hBAT-1), or a fragment thereof. Pidilizumab and other humanized PD-I monoclonal antibodies are disclosed in US 2008 / 0025980 and WO 2009 / 101611, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, the anti-PD-1 antibody or antigen-binding fragment thereof for use in the methods provided herein comprises a light chain variable region comprising an amino acid sequence selected from SEQ ID NOs: 15-18 of US 2008 / 0025980: SEQ ID NO: 15 of US 2008 / 0025980 (SEQ ID NO: 5): EIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWYQQKPGKAPKLLIYRTSNLASGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIK; SEQ ID NO: 16 (SEQ ID NO: 6) of US 2008 / 0025980: EIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWFQQKPGKAPKLWIYRTSNLASGVPSRFSGSGSGTDYTLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIK; SEQ ID NO: 17 of US 2008 / 0025980 (SEQ ID NO: 7): EIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWFQQKPGKAPKLWIYRTSNLASGVPSRFSGSGSGTDYCLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIK; SEQ ID NO:18 of US 2008 / 0025980 (SEQ ID NO:8): EIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWFQQKPGKAPKLWIYRTSNLASGVPSRFSGSGSGTSYCLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIK; and / or a heavy chain comprising an amino acid sequence selected from SEQ ID NOs: 20-24 of US 2008 / 0025980: SEQ ID NO:20 (SEQ ID NO:9) of US 2008 / 0025980: QVQLVQSGSELKKPGASVKISCKASGYSFSNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVSTAYLQITSLTAEDTGMYFCAKVGYDALDYWGQGTLVTVSS; SEQ ID NO:21 (SEQ ID NO:10) of US 2008 / 0025980: QVQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVSTAYLQITSLTAEDTGMYFCAKVGYDALDYWGQGTLVTVSS; SEQ ID NO:22 (SEQ ID NO:11) of US 2008 / 0025980: QVQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVNTAYLQITSLTAEDTGMYFCVRVGYDALDYWGQGTLVTVSS; SEQ ID NO:23 (SEQ ID NO:12) of US 2008 / 0025980: QIQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVNTAYLQITSLTAEDTGMYFCVRVGYDALDYWGQGTLVTVSS; SEQ ID NO:24 (SEQ ID NO:13) of US 2008 / 0025980: QIQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTDSGESTYAEEFKGRFAFSLDTSVNTAYLQITSLNAEDTGMYFCVRVGYDALDYWGQGTLVTVSS Includes.

[0021] In one embodiment, the targeting moiety comprises a light chain comprising SEQ ID NO: 18 of US 2008 / 0025980 and a heavy chain comprising SEQ ID NO: 22 of US 2008 / 0025980.

[0022] In one embodiment, the targeting moiety comprises AMP-514 (also known as MEDI-0680).

[0023] In one embodiment, the targeting moiety comprises the PD-L2-Fc fusion protein AMP-224, as disclosed in WO 2010 / 027827 and WO 2011 / 066342, the entire disclosures of which are incorporated herein by reference. In such an embodiment, the targeting moiety comprises a targeting domain comprising SEQ ID NO:4 of WO2010 / 027827: LFTVTVPKELYIIEHGSNVTLECNFDTGSHVNLGAITASLQKVENDTSPHRERATLLEEQLPLGKASFHIPQVQVRDEGQYQCIIIYGVAWDYKYLTLKVKASYRKINTHILKVPETDEV ELTCQATGYPLAEVSWPNVSVPANTSHSRTPEGLYQVTSVLRLKPPPGRNFSCVFWNTHVRELTLASIDLQSQMEPRTHPTWLLHIFIPFCIIAFIFIATVIALRKQLCQKLYSSKDTTK RPVTTTKREVNSAI (SEQ ID NO: 14) and / or a B7-DC fusion protein comprising SEQ ID NO: 83 of WO2010 / 027827: MIFLLLMLSLELQLHQIAALFTVTVPKELYIIEHGSNVTLECNFDTGSHVNLGAITASLQKVENDTSPHRERATLLEEQLPLGKASFHIPQVQVRDEGQYQCIIIYGVAWDYKYL TLKVKASYRKINTHILKVPETDEVELTCQATGYPLAEVSWPNVSVPANTSHSRTPEGLYQVTSVLRLKPPPGRNFSCVFWNTHVRELTLASIDLQSQMEPRTHPTWEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 15) may include:

[0024] In one embodiment, the targeting moiety comprises the peptide AUNP12 or any of the other peptides disclosed in US 2011 / 0318373 or 8,907,053. For example, the targeting moiety is: SNTSESFK (SNTSESF) FRVTQLAPKAQIKE-NH2 (SEQ ID NO: 16) [ka] (i.e. compound 8 or SEQ ID NO: 49 of US 2011 / 0318373).

[0025] In one embodiment, the targeting moiety comprises the anti-PD-1 antibody 1E3, or a fragment thereof, as disclosed in US 2014 / 0044738, the entire disclosure of which is incorporated herein by reference. In an exemplary embodiment, 1E3 or an antigen-binding fragment thereof for use in the methods provided herein comprises: EVQLQQSGPV LVKPGASVKM SCKASGYTFT DYYMNWVKQS HGKSLEWIGN INPYNGGTTY NQKFKGKATL TVDKSSRTAY MEINSLTSED SAVYYCARGR IYDGSLDYWG QGTALTVSS (SEQ ID NO:17) and / or a heavy chain variable region comprising the amino acid sequence of: DIQMTQFPSS LCASQGGKVT VTCKASQDIN NYMAWYQHKP GKGPRLLIHY TSTLLSGIPS RFSGSGSGRD YSFSISNLEP EDIATYYCLQ YDNLWTFGGG TKLEIK (SEQ ID NO:18) The light chain variable region comprises the amino acid sequence of:

[0026] In one embodiment, the targeting moiety comprises the anti-PD-1 antibody 1E8, or a fragment thereof, as disclosed in US 2014 / 0044738, the entire disclosure of which is incorporated herein by reference. In an exemplary embodiment, 1E8 or an antigen-binding fragment thereof for use in the methods provided herein comprises: QVQLQQSGAE LAKPGASVRL SCKASGYTFT NYWMHWVKQR PGQGLEWIGH INPSSGFTTY NQNFKDKATL TADKSSNTAY MQLSSLTYED SAVYFCARED YDVDYWGQGT TLTVSS (SEQ ID NO:19) and / or a heavy chain variable region comprising the amino acid sequence of: DIVMTQSQKF MSTSVGDRVS VTCKASQSVD TNVAWYQQKP GQSPKALIFS ASYRYSGVPD RFTGSGSGTD FTLTINSVQS EDLAEYFCQQ YNSYPYTFGS GTKLEIK (SEQ ID NO:20) The light chain variable region comprises the amino acid sequence of:

[0027] In one embodiment, the targeting moiety comprises the anti-PD-1 antibody 1H3, or a fragment thereof, as disclosed in US 2014 / 0044738, the entire disclosure of which is incorporated herein by reference. In an exemplary embodiment, 1H3 or an antigen-binding fragment thereof for use in the methods provided herein comprises: EVQLVESGGG LVKPGGSLKL SCAASGFTFS DYGMHWVRQA PEKGLEWVAY ISSGSYTIYY TDTVKGRFTI SRDNAKNTLF LQMTSLRSED TAMYYCARRG YGSFYEYYFD YWGQGTTLTV SS (SEQ ID NO:21) and / or a heavy chain variable region comprising the amino acid sequence of: QIVLTQSPAL MSASPGEKVT MTCSASSSVS YMYWYQQKPR SSPKPWIYLT SNLASGVPAR FSGSGSGTSY SLTISSMEAE DAATYYCQQW SSNPFTFGSG TKLEIK (SEQ ID NO:22) The light chain variable region comprises the amino acid sequence of:

[0028] In one embodiment, the targeting moiety comprises a VHH directed against PD-1, e.g., as disclosed in US 8,907,065 and WO 2008 / 071447, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, the VHH directed against PD-1 is set forth in SEQ ID NOs: 347-351 of US 8,907,065: SEQ ID NO: 347 of US 8,907,065 (SEQ ID NO: 23): EVQLVESGGGLVQAGKSLRLSCAASGSIFSIHAMGWFRQAPGKEREFVAAITWSGGITYYEDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAIYYCAADRAESSWYDYWGQGTQVTVSS; SEQ ID NO:348 of US 8,907,065 (SEQ ID NO:24): EVQLVESGGGLVQAGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAIYYCAGDKHQSSWYDYWGQGTQVTVSS; SEQ ID NO: 349 of US 8,907,065 (SEQ ID NO: 25): EVQLVESGGGLVQAGGSLRLSCAASGSISSIHAMGWFRQAPGKEREFVAAITWSGGITYYADSLKGRFTISRDNAKNTGYLQMNSLKPEDTAIYYCAADRAQSSWYDYWGQGTQVTVSS; SEQ ID NO:350 of US 8,907,065 (SEQ ID NO:26): EVQLVESGGGLVQAGGSLGLSCAASGSIFSINAMAWFRQAPGKEREFVALISWSGGSTYYEDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAIYYCAADRVDSNWYDYWGQGTQVTVSS; SEQ ID NO: 351 (SEQ ID NO: 27) of US 8,907,065: EVQLVESGGGLVQAGGSLRLSCAASGRAFSSGTMGWFRRAPGKEREFVASIPWSGGRIYYADSVKGRFTISRDNAQNTVYLQMNSLKPEDTAVYYCAVKERSTGWDFASWGQCTQVTVSS Includes.

[0029] In one embodiment, the targeting moiety comprises any one of the anti-PD-1 antibodies or fragments thereof as disclosed in US2011 / 0271358 and WO2010 / 036959, the entire contents of which are incorporated herein by reference. In an exemplary embodiment, the antibody or antigen-binding fragment for use in the methods provided herein is set forth in SEQ ID NOs:25-29 of US2011 / 0271358: SEQ ID NO:25 of US2011 / 0271358 (SEQ ID NO:28): QVQLVQSGAELKQPGASVKMSCKASGYSFTSSWIHWVKQAPGQGLEWIGYIYPSTGFTEYNQKFKDRATLTADKSTSTAYMELSSLRSEDSAVYYCARWRDSSGYHAMDYWGQGTSVTVS S; SEQ ID NO:26 (SEQ ID NO:29) of US2011 / 0271358: QVQLVQSGAEVKQPGASVKMSCKASGYSFTSSWIHWVKQAPGQGLEWIGYIYPSTGFTEYNQKFKDRATLTADKSTSTAYMELSSLRSEDTAVYY3 / d10CARWRDSSGYHAMDYWGQGTSVTVSS; SEQ ID NO:27 (SEQ ID NO:30) of US2011 / 0271358: QVQLVQSGHEVKQPGASVKMSCKASGYSFTSSWIHWVKQAPGQGLEWIGYIYPSTGFTEYNQKFKDRATLTADKSTSTAYMELSSLRSEDTAVYYCARWRDSSGYHAMDYWGQGTLVTVSS; SEQ ID NO:28 (SEQ ID NO:31) of US2011 / 0271358: QVQLVQSGHEVKQPGASVKMSCKASGYSFTSSWIHWVRQAPGQGLEWIGYIYPSTGFTEYNQKFKDRATLTADKSTSTAYMELSSLRSEDTAVYYCARWRDSSGYHAMDYWGQGTLVTVSS; SEQ ID NO:29 (SEQ ID NO:32) of US2011 / 0271358: QVQLVQSGHEVKQPGASVKVSCKASGYSFTSSWIHWVRQAPGQGLEWIGYIYPSTGFTEYNQKFKDRATITADKSTSTAYMELSSLRSEDTAVYYCARWRDSSGYHAMDYWGQGTLVTVSS and / or a heavy chain comprising an amino acid sequence selected from SEQ ID NOs: 30-33 of US2011 / 0271358: SEQ ID NO:30 (SEQ ID NO:33) of US2011 / 0271358: DIVLTQSPASLTLSPGQRLTISCRASQSVSTSGYSYMHWYQQKPDQSPKLLIKFGSNLESGIPARFSGSGSGTDFTLTISSLEEEDFATYYCQHSWEIPYTFGQGTKLEIK; SEQ ID NO:31 (SEQ ID NO:34) of US2011 / 0271358: DIVLTQSPATLSLSPGQRLTISCRASQSVSTSGYSYMHWYQQKPDQSPKLLIKFGSNLESGIPARFSGSGSGTDFTLTISSLEPEDFATYYCQHSWEIPYTFGQGTKLEIK; SEQ ID NO:32 (SEQ ID NO:35) of US2011 / 0271358: EIVLTQSPATLSLSPGQRLTISCRASQSVSTSGYSYMHWYQQKPDQSPKLLIKFGSNLESGIPARFSGSGSGTDFTLTISSLEPEDFATYYCQHSWEIPYTFGQGTKLEIK; SEQ ID NO:33 (SEQ ID NO:36) of US2011 / 0271358: DIVLTQSPATLSLSPGQRLTISCRASQSVSTSGYSYMHWYQQKPDQSPKLLIKFGSNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSWEIPYTFGQGTKLEIK The light chain comprises an amino acid sequence selected from:

[0030] In various embodiments, the chimeric protein of the present invention comprises an antibody directed against PD-1 selected from TSR-042 (Tesaro, Inc.), REGN2810 (Regeneron Pharmaceuticals, Inc.), PDR001 (Novartis Pharmaceuticals), and BGB-A317 (BeiGene Ltd.), or an antibody fragment thereof.

[0031] In various embodiments, the chimeric proteins of the invention have one targeting moiety directed against PD-L1. In some embodiments, the chimeric protein has one targeting moiety that selectively binds a PD-L1 polypeptide. In some embodiments, the chimeric protein comprises an antibody, an antibody derivative or form, a peptide or polypeptide, or a fusion protein that selectively binds a PD-L1 polypeptide.

[0032] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody MEDI4736 (also known as durvalumab), or a fragment thereof. MEDI4736 is selective for PD-L1 and blocks the binding of PD-L1 to the PD-1 and CD80 receptors. MEDI4736 and antigen-binding fragments thereof for use in the methods provided herein comprise heavy and light chains or heavy and light chain variable regions. The sequence of MEDI4736 is disclosed in WO / 2016 / 06272, the entire contents of which are incorporated herein by reference. In an exemplary embodiment, MEDI4736 or antigen-binding fragments thereof for use in the methods provided herein comprise: EVQLVESGGG LVQPGGSLRL SCAASGFTFS RYWMSWVRQA PGKGLEWVAN IKQDGSEKYY VDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREG GWFGELAFDY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PCPPAPEFEG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPASIEKTI SKAKGQPREP QVYTLPSRE EMTKNQVSLT CLVKGFYPSD ​​IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K (SEQ ID NO:37) and / or a heavy chain comprising the amino acid sequence of: EIVLTQSPGT LSLSPGERAT LSCRASQRVS SSYLAWYQQK PGQAPRLLIY DASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSLPWTFG QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC (SEQ ID NO:38) and a light chain comprising the amino acid sequence of

[0033] In an exemplary embodiment, MEDI4736 or an antigen-binding fragment thereof for use in the methods provided herein has the amino acid sequence of SEQ ID NO:4 of WO / 2016 / 06272: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS (SEQ ID NO: 39) and / or the amino acid sequence of SEQ ID NO:3 of WO / 2016 / 06272: EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK (SEQ ID NO: 40) The light chain variable region comprises:

[0034] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody atezolizumab (also known as MPDL3280A, RG7446), or a fragment thereof. In an exemplary embodiment, atezolizumab or an antigen-binding fragment thereof for use in the methods provided herein comprises: EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 41) and / or a heavy chain comprising the amino acid sequence of: DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 42) and a light chain comprising the amino acid sequence of

[0035] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody avelumab (also known as MSB0010718C), or a fragment thereof. In an exemplary embodiment, avelumab or an antigen-binding fragment thereof for use in the methods provided herein comprises: EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYIMMWVRQA PGKGLEWVSS IYPSGGITFY ADTVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARIK LGTVTTVDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK (SEQ ID NO:43) and / or a heavy chain comprising the amino acid sequence of: QSALTQPASV SGSPGQSITI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YDVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYTSSSTRV FGTGTKVTVL GQPKANPTVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKADGSPVK AGVETTKPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT HEGSTVEKTV APTECS (SEQ ID NO:44) and a light chain comprising the amino acid sequence of

[0036] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody BMS-936559 (also known as 12A4, MDX-1105), or a fragment thereof, as disclosed in US 2013 / 0309250 and WO2007 / 005874, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, BMS-936559, or an antigen-binding fragment thereof, for use in the methods provided herein comprises: QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSS (SEQ ID NO: 45) and / or a heavy chain variable region comprising the amino acid sequence of: EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIK (SEQ ID NO: 46) The light chain variable region comprises the amino acid sequence of:

[0037] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 3G10, or a fragment thereof, as disclosed in US 2013 / 0309250 and WO2007 / 005874, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 3G10, or an antigen-binding fragment thereof, for use in the methods provided herein comprises: QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYGFSWVRQAPGQGLEWMGWITAYNGNTNYAQKLQGRVTMTTDTSTSTVYMELRSLRSDDTAVYYCARDYFYGMDVWGQGTTVTVSS (SEQ ID NO: 47) and / or a heavy chain variable region comprising the amino acid sequence of: EIVLTQSPATLSLSPGERATLSCRASQSVSSYLVWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK (SEQ ID NO: 48) The light chain variable region comprises the amino acid sequence of:

[0038] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 10A5, or a fragment thereof, as disclosed in US 2013 / 0309250 and WO2007 / 005874, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 10A5 or an antigen-binding fragment thereof for use in the methods provided herein comprises: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDVHWVRQAPGQRLEWMGWLHADTGITKFSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARERIQLWFDYWGQGTLVTVSS (SEQ ID NO: 49) and / or a heavy chain variable region comprising the amino acid sequence of: DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK (SEQ ID NO: 50) The light chain variable region comprises the amino acid sequence of:

[0039] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 5F8, or a fragment thereof, as disclosed in US 2013 / 0309250 and WO2007 / 005874, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 5F8 or an antigen-binding fragment thereof for use in the methods provided herein comprises: QVQLVQSGAEVKKPGSSVKVSCKVSGGIFSTYAINWVRQAPGQGLEWMGGIIPIFGTANHAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDQGIAAALFDYWGQGTLVTVSS (SEQ ID NO: 51) and / or a heavy chain variable region comprising the amino acid sequence of: EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK (SEQ ID NO: 52) The light chain variable region comprises the amino acid sequence of:

[0040] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 10H10, or a fragment thereof, as disclosed in US 2013 / 0309250 and WO2007 / 005874, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 10H10, or an antigen-binding fragment thereof, for use in the methods provided herein comprises: EVQLVESGGGLVQPGRSLRLSCAVSGFTFDDYVVHWVRQAPGKGLEWVSGISGNSGNIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAVPFDYWGQGTLVTVSS (SEQ ID NO: 53) and / or a heavy chain variable region comprising the amino acid sequence of: DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK (SEQ ID NO: 54) The light chain variable region comprises the amino acid sequence of:

[0041] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 1B12, or a fragment thereof, as disclosed in US 2013 / 0309250 and WO2007 / 005874, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 1B12 or an antigen-binding fragment thereof for use in the methods provided herein comprises: QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSSYAISWVRQAPGQGLEWMGGIIPIFGRAHYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSS (SEQ ID NO: 55) and / or a heavy chain variable region comprising the amino acid sequence of: EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIK (SEQ ID NO: 56) The light chain variable region comprises the amino acid sequence of:

[0042] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 7H1, or a fragment thereof, as disclosed in US 2013 / 0309250 and WO2007 / 005874, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 7H1 or an antigen-binding fragment thereof for use in the methods provided herein comprises: QVQLVQSGAEVKKPGSSVKVSCKTSGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQKFQGRVTITADESTTTAYMELSSLRSEDTAVYYCARKYDYVSGSPFGMDVWGQGTTVTVSS (SEQ ID NO: 57) and / or a heavy chain variable region comprising the amino acid sequence of: EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIK (SEQ ID NO: 58) The light chain variable region comprises the amino acid sequence of:

[0043] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 11E6, or a fragment thereof, as disclosed in US 2013 / 0309250 and WO2007 / 005874, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 11E6 or an antigen-binding fragment thereof for use in the methods provided herein comprises: QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAINWVRQAPGQGLEWMGGIIPIFGSANYAQKFQDRVTITADESTSAAYMELSSLRSEDTAVYYCARDSSGWSRYYMDVWGQGTTVTVSS (SEQ ID NO: 59) and / or a heavy chain variable region comprising the amino acid sequence of: EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPFGGGTKVEIK (SEQ ID NO: 60) The light chain variable region comprises the amino acid sequence of:

[0044] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 12B7, or a fragment thereof, as disclosed in US 2013 / 0309250 and WO2007 / 005874, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 12B7 or an antigen-binding fragment thereof for use in the methods provided herein comprises: QVQLVQSGAEVKEPGSSVKVSCKASGGTFNSYAISWVRQAPGQGLEWMGGIIPLFFGIAHYAQKFQGRVTITADESTNTAYMDLSSLRSEDTAVYYCARKYSYVSGSPFGMDVWGQGTTVT VSS (SEQ ID NO:61) and / or a heavy chain variable region comprising the amino acid sequence of: EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTRLEIK (SEQ ID NO: 62) The light chain variable region comprises the amino acid sequence of:

[0045] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 13G4, or a fragment thereof, as disclosed in US 2013 / 0309250 and WO2007 / 005874, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 13G4 or an antigen-binding fragment thereof for use in the methods provided herein comprises: EVQLVESGGGLVQPGRSLRLSCAASGITFDDYGMHWVRQAPGKGLEWVSGISWNRGRIEYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKGRFRYFDWFLDYWGQGTLVTVSS (SEQ ID NO: 63) and / or a heavy chain variable region comprising the amino acid sequence of: AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPFTFGPGTKVDIK (SEQ ID NO: 64) The light chain variable region comprises the amino acid sequence of:

[0046] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 1E12, or a fragment thereof, as disclosed in US 2014 / 0044738, the entire disclosure of which is incorporated herein by reference. In an exemplary embodiment, 1E12 or an antigen-binding fragment thereof for use in the methods provided herein comprises: EVKLQESGPS LVKPSQTLSL TCSVTGYSIT SDYWNWIRKF PGNKLEYVGY ISYTGSTYYN PSLKSRISIT RDTSKNQYYL QLNSVTSEDT ATYYCARYGG WLSPFDYWGQ GTTLTVSS (SEQ ID NO:65) and / or a heavy chain variable region comprising the amino acid sequence of: DIVMTQSHKL MSTSVGDRVS ITCKASQDVG TAVAWYQQKP GQSPKLLIYW ASTRHTGVPD RFTGSGSGTD FTLTISNVQS EDLADYFCQQ DSSYPLTFGA GTKVELK (SEQ ID NO:66) The light chain variable region comprises the amino acid sequence of:

[0047] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 1F4, or a fragment thereof, as disclosed in US 2014 / 0044738, the entire disclosure of which is incorporated herein by reference. In an exemplary embodiment, 1F4 or an antigen-binding fragment thereof for use in the methods provided herein comprises: EVQLQESGPG LVAPSQSLSI TCTVSGFSLT TYSINWIRQP PGKGLEWLGV MWAGGGTNSN SVLKSRLIIS KDNSKSQVFL KMNSLQTDDT ARYYCARYYG NSPYYAIDYW GQGTSVTVSS (SEQ ID NO:67) and / or a heavy chain variable region comprising the amino acid sequence of: DIVTTQSHKL MSTSVGDRVS ITCKASQDVG TAVAWYQQKP GQSPKLLIYW ASTRHTGVPD RFTGSGSGTD FTLTISNVQS EDLADYFCQQ DSSYPLTFGA GTKVELK (SEQ ID NO:68) The light chain variable region comprises the amino acid sequence of:

[0048] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 2G11, or a fragment thereof, as disclosed in US 2014 / 0044738, the entire disclosure of which is incorporated herein by reference. In an exemplary embodiment, 2G11, or an antigen-binding fragment thereof, for use in the methods provided herein comprises: EVKLQESGPS LVKPSQTLSL TCSVTGYSII SDYWNWIRKF PGNKLEYLGY ISYTGSTYYN PSLKSRISIT RDTSKNQYYL QLNSVTTEDT ATYYCARRGG WLLPFDYWGQ GTTLTVSS (SEQ ID NO:69) and / or a heavy chain variable region comprising the amino acid sequence of: DIVMTQSPSS LAVSVGEKVS MGCKSSQSLL YSSNQKNSLA WYQQKPGQSP KLLIDWASTR ESGVPDRFTG SGSGTDFTLT ISSVKAEDLA VYYCQQYYGY PLTFGAGTKL ELK (SEQ ID NO:70) The light chain variable region comprises the amino acid sequence of:

[0049] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 3B6, or a fragment thereof, as disclosed in US 2014 / 0044738, the entire disclosure of which is incorporated herein by reference. In an exemplary embodiment, 3B6 or an antigen-binding fragment thereof for use in the methods provided herein comprises: EVKLQESGPS LVKPGASVKL SCKASGYTFT SYDINWVKQR PGQGLEWIGW IFPRDNNTKY NENFKGKATL TVDTSSTTAY MELHSLTSED SAVYFCTKEN WVGDFDYWGQ GTTLTLSS (SEQ ID NO:71) and / or a heavy chain variable region comprising the amino acid sequence of: DIVMTQSPAI MSASPGEKVT MTCSASSSIR YMHWYQQKPG TSPKRWISDT SKLTSGVPAR FSGSGSGTSY ALTISSMEAE DAATYYCHQR SSYPWTFGGG TKLEIK (SEQ ID NO:72) The light chain variable region comprises the amino acid sequence of:

[0050] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 3D10, or a fragment thereof, as disclosed in US 2014 / 0044738 and WO2012 / 145493, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 3D10 or an antigen-binding fragment thereof for use in the methods provided herein comprises: EVQLQQSGPD LVTPGASVRI SCQASGYTFP DYYMNWVKQS HGKSLEWIGD IDPNYGGTTY NQKFKGKAIL TVDRSSSTAY MELRSLTSED SAVYYCARGA LTDWGQGTSL TVSS (SEQ ID NO:73) and / or a heavy chain variable region comprising the amino acid sequence of: QIVLSQSPAI LSASPGEKVT MTCRASSSVS YIYWFQQKPG SSPKPWIYAT FNLASGVPAR FSGSGSGTSY SLTISRVETE DAATYYCQQW SNNPLTFGAG TKLELK (SEQ ID NO:74) The light chain variable region comprises the amino acid sequence of:

[0051] In one embodiment, the targeting moiety comprises any one of the anti-PD-L1 antibodies disclosed in US2011 / 0271358 and WO2010 / 036959, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, the antibody or antigen-binding fragment thereof for use in the methods provided herein is set forth in SEQ ID NOs: 34-38 of US2011 / 0271358: SEQ ID NO:34 (SEQ ID NO:75) of US2011 / 0271358: EVQLVQSGPELKKPGASVKMSCKASGYTFTSYVMHWVKQAPGQRLEWIGYVNPFNDGTKYNEMFKGRATLTSDKSTSTAYMELSSLRSEDSAVYYCARQAWGYPWGQGTLVTVSS; SEQ ID NO:35 of US2011 / 0271358 (SEQ ID NO:76): EVQLVQSGAEVKKPGASVKMSCKASGYTFTSYVMHWVKQAPGQRLEWIGYVNPFNDGTKYNEMFKGRATLTSDKSTSTAYMELSSLRSEDTAVYYCARQAWGYPWGQGTLVTVSS; SEQ ID NO:36 (SEQ ID NO:77) of US2011 / 0271358: EVQLVQSGAEVKKPGASVKMSCKASGYTFTSYVMHWVRQAPGQRLEWIGYVNPFNDGTKYNEMFKGRATLTSDKSTSTAYMELSSLRSEDTAVYYCARQAWGYPWGQGTLVTVSS; SEQ ID NO:37 (SEQ ID NO:78) of US2011 / 0271358: EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQRLEWIGYVNPFNDGTKYNEMFKGRATLTSDKSTSTAYMELSSLRSEDTAVYYCARQAWGYPWGQGTLVTVSS; SEQ ID NO:38 (SEQ ID NO:79) of US2011 / 0271358: EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQRLEWIGYVNPFNDGTKYNEMFKGRATITSDKSTSTAYMELSSLRSEDTAVYYCARQAWGYPWGQGTLVTVSS; and / or a heavy chain comprising an amino acid sequence selected from SEQ ID NOs: 39-42 of US2011 / 0271358: SEQ ID NO:39 (SEQ ID NO:80) of US2011 / 0271358: DIVLTQSPASLALSPGERATLSCRATESVEYYGTSLVQWYQQKPGQPPKLLIYAASSVDSGVPSRFSGSGSGTDFTLTINSLEEEDAAMYFCQQSRRVPYTFGQGTKLEIK; SEQ ID NO: 40 of US2011 / 0271358 (SEQ ID NO: 81): DIVLTQSPATLLSPGERATLSCRATESVEYYGTSLVQWYQQKPGQPPKLLIYAASSVDSGVPSRFSGSGSGTDFTLTINSLEAEDAAMYFCQQSRRVPYTFGQGTKLEIK; SEQ ID NO: 41 (SEQ ID NO: 82) of US2011 / 0271358: EIVLTQSPATLLSPGERATLSCRATESVEYYGTSLVQWYQQKPGQPPKLLIYAASSVDSGVPSRFSGSGSGTDFTLTINSLEAEDAAMYFCQQSRRVPYTFGQGTKLEIK; SEQ ID NO: 42 of US2011 / 0271358 (SEQ ID NO: 83): DIVLTQSPATLLSPGERATLSCRATESVEYYGTSLVQWYQQKPGQPPKLLIYAASSVDSGVPSRFSGSGSGTDFTLTINSLEAEDAATYFCQQSRRVPYTFGQGTKLEIK The light chain comprises an amino acid sequence selected from:

[0052] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 2.7A4, or a fragment thereof, as disclosed in WO 2011 / 066389, US8,779,108, and US2014 / 0356353, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 2.7A4 or an antigen-binding fragment thereof for use in the methods provided herein comprises: SEQ ID NO:2 (SEQ ID NO:84) of WO 2011 / 066389: EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYSMNWVRQAPGKGLEWVSSISSSGDYIYYADSVKGRFTISRDNAKNSLFLQMNSLKAEDTAVYYCARDLVTSMVAFDYWGQGTLVTVSS and / or a heavy chain variable region comprising the amino acid sequence of: SEQ ID NO: 7 (SEQ ID NO: 85) of WO 2011 / 066389: SYELTQPPSVSVSPGQAARITCSGDALPQKYVFWYQQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDRSGNHRVFGGGGTRLTVL The light chain variable region comprises the amino acid sequence of:

[0053] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 2.9D10, or a fragment thereof, as disclosed in WO 2011 / 066389, US8,779,108, and US2014 / 0356353, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 2.9D10, or an antigen-binding fragment thereof, for use in the methods provided herein comprises: SEQ ID NO: 12 (SEQ ID NO: 86) of WO 2011 / 066389: EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGGEQYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDWNYGYYDMDVWGQGTTVTVSS and / or a heavy chain variable region comprising the amino acid sequence of: SEQ ID NO: 17 (SEQ ID NO: 87) of WO 2011 / 066389: EIVLTQSPGTLSLSPGERATLSCRASQSVSSNYLAWFQQKPGQAPRLLIFGTSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSIFTFGPGTKVDIK The light chain variable region comprises the amino acid sequence of:

[0054] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 2.14H9, or a fragment thereof, as disclosed in WO 2011 / 066389, US8,779,108, and US2014 / 0356353, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 2.14H9, or an antigen-binding fragment thereof, for use in the methods provided herein comprises: SEQ ID NO: 22 (SEQ ID NO: 88) of WO 2011 / 066389: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVS S and / or a heavy chain variable region comprising the amino acid sequence of: SEQ ID NO: 27 (SEQ ID NO: 89) of WO 2011 / 066389: EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTEVEIK The light chain variable region comprises the amino acid sequence of:

[0055] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 2.20A8, or a fragment thereof, as disclosed in WO 2011 / 066389, US8,779,108, and US2014 / 0356353, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 2.20A8, or an antigen-binding fragment thereof, for use in the methods provided herein comprises: SEQ ID NO: 32 (SEQ ID NO: 90) of WO 2011 / 066389: EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSAIRGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLHYDSSGYLDYWGQGTLVTVSS and / or a heavy chain variable region comprising the amino acid sequence of: SEQ ID NO: 37 (SEQ ID NO: 91) of WO 2011 / 066389: DIQMTQSPSSVSASVGDRVTITCRASQGIRSWLAWYQQKPGKAPKLLIYAISRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK The light chain variable region comprises the amino acid sequence of:

[0056] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 3.15G8, or a fragment thereof, as disclosed in WO 2011 / 066389, US8,779,108, and US2014 / 0356353, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 3.15G8 or an antigen-binding fragment thereof for use in the methods provided herein comprises: SEQ ID NO: 42 (SEQ ID NO: 92) of WO 2011 / 066389: EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGGEKYYVDSVKGRFTISRDNAKNSLFLQMNSLRAEDTAVYYCARVQLYSDYFDYWGQGTLVTVSS and / or a heavy chain variable region comprising the amino acid sequence of: SEQ ID NO: 47 (SEQ ID NO: 93) of WO 2011 / 066389: DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKSGKAPKLLIYAASGLQSGVPSRFSGSGSGTDFTLTISSLQPEDLATYYCQQSHSLPPTFGQGTKVEIK The light chain variable region comprises the amino acid sequence of:

[0057] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 3.18G1, or a fragment thereof, as disclosed in WO 2011 / 066389, US8,779,108, and US2014 / 0356353, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 3.18G1 or an antigen-binding fragment thereof for use in the methods provided herein comprises: SEQ ID NO: 52 (SEQ ID NO: 94) of WO 2011 / 066389: EVQLLESGGDLVQPGGSLRLSCAASGFTFNSYAMSWVRQAPGKGLEWVSTISGSGGFTFSADSVKGRFTISRDNSKNTLFLQMNSLRVEDSAAVYSCAKVLVGFNNGCWDYWGQGTLVTVSS and / or a heavy chain variable region comprising the amino acid sequence of: SEQ ID NO: 57 (SEQ ID NO: 95) of WO 2011 / 066389: SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSNDHVVFGGGTKLTVL The light chain variable region comprises the amino acid sequence of:

[0058] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 2.7A4OPT, or a fragment thereof, as disclosed in WO 2011 / 066389, US8,779,108, and US2014 / 0356353, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 2.7A4OPT, or an antigen-binding fragment thereof, for use in the methods provided herein comprises: SEQ ID NO: 62 (SEQ ID NO: 96) of WO 2011 / 066389: EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYSMNWVRQAPGKGLEWVSSISSSGDYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLVTSMVAFDYWGQGTLVTVSS and / or a heavy chain variable region comprising the amino acid sequence of: SEQ ID NO: 67 (SEQ ID NO: 97) of WO 2011 / 066389: SYELTQPPSVSVSPGQTARITCSGDALPQKYVFWYQQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDRSGNHRVFGGGTKLTVL The light chain variable region comprises the amino acid sequence of:

[0059] In one embodiment, the targeting moiety comprises the anti-PD-L1 antibody 2.14H9OPT, or a fragment thereof, as disclosed in WO 2011 / 066389, US8,779,108, and US2014 / 0356353, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, 2.14H9OPT, or an antigen-binding fragment thereof, for use in the methods provided herein comprises: SEQ ID NO: 72 (SEQ ID NO: 98) of WO 2011 / 066389: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS and / or a heavy chain variable region comprising the amino acid sequence of: SEQ ID NO: 77 (SEQ ID NO: 99) of WO 2011 / 066389: EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK The light chain variable region comprises the amino acid sequence of:

[0060] In one embodiment, the targeting moiety comprises any one of the anti-PD-L1 antibodies disclosed in WO2016 / 061142, the entire contents of which are incorporated herein by reference. In an exemplary embodiment, the antibody or antigen-binding fragment thereof for use in the methods provided herein is set forth in SEQ ID NOs: 18, 30, 38, 46, 50, 54, 62, 70, and 78 of WO2016 / 061142: SEQ ID NO: 18 (SEQ ID NO: 100) of WO2016 / 061142: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMYWVRQATGQGLEWMGRIDPNSGSTKYNEKFKNRFTISRDDSKNTAYLQMNSLKTEDTAVYYCARDYRKGLYAMDYWGQGTTVTVSS; SEQ ID NO: 30 (SEQ ID NO: 101) of WO2016 / 061142: EVQLVQSGAEVKKPGATVKISCKVSGYTFTSYWMYWVRQATGQGLEWMGRIDPNSGSTKYNEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCARDYRKGLYAMDYWGQGTTVTVSS; SEQ ID NO: 38 (SEQ ID NO: 102) of WO2016 / 061142: EVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMYWVRQAPGQGLEWMGRIDPNSGSTKYNEKFKNRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYRKGLYAMDYWGQGTTVTVSS; SEQ ID NO: 46 (SEQ ID NO: 103) of WO2016 / 061142: EVQLVQSGAEVKKPGATVKISCKVSGYTFTSYWMYWIRQSPSRGLEWLGRIDPNSGSTKYNEKFKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARDYRKGLYAMDYWGQGTTVTVSS; SEQ ID NO: 50 (SEQ ID NO: 104) of WO2016 / 061142: EVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMYWIRQPPGKGLEWIGRIDPNSGSTKYNEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCARDYRKGLYAMDYWGQGTTVTVSS; SEQ ID NO:54 (SEQ ID NO:105) of WO2016 / 061142: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMYWIRQSPSRGLEWLGRIDPNSGSTKYNEKFKNRFTISRDDSKNTAYLQMNSLKTEDTAVYYCARDYRKGLYAMDYWGQGTTVTVSS; SEQ ID NO: 62 (SEQ ID NO: 106) of WO2016 / 061142: EVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMYWVRQARGQRLEWIGRIDPNSGSTKYNEKFKNRLTISKDTSKNQVVLTMTTNMDPVDTATYYCARDYRKGLYAMDYWGQGTTVTVSS; SEQ ID NO: 70 (SEQ ID NO: 107) of WO2016 / 061142: QITLKESGPTLVKPTQTLTLTCTFSGYTFTSYWMYWVRQAPGKGLEWVSRIDPNSGSTKYNEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCARDYRKGLYAMDYWGQGTTVTVSS; SEQ ID NO: 78 (SEQ ID NO: 108) of WO2016 / 061142: EVQLVQSGAEVKKPGATVKISCKVSGYTFTSYWMYWVRQARGQRLEWIGRIDPNSGSTKYNEKFKNRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDYRKGLYAMDYWGQGTTVTVSS and / or a heavy chain comprising an amino acid sequence selected from SEQ ID NOs: 22, 26, 34, 42, 58, 66, 74, 82, and 86 of US2016 / 061142: SEQ ID NO: 22 (SEQ ID NO: 109) of WO2016 / 061142: DIVMTQTPLSLPVTPGEPASISCKASQDVGTAVAWYLQKPGQSPQLLIYWASTRHTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNSYPLTFGQGTKVEIK; SEQ ID NO: 26 (SEQ ID NO: 110) of WO2016 / 061142: DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYLQKPGQSPQLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPLTFGQGTKVEIK; SEQ ID NO: 34 (SEQ ID NO: 111) of WO2016 / 061142: EIVLTQSPDFQSVTPKEKVTITCKASQDVGTAVAWYLQKPGQSPQLLIYWASTRHTGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQYNSYPLTFGQGTKVEIK; SEQ ID NO: 42 (SEQ ID NO: 112) of WO2016 / 061142: EIVLTQSPDFQSVTPKEKVTITCKASQDVGTAVAWYLQKPGQSPQLLIYWASTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYNSYPLTFGQGTKVEIK. SEQ ID NO:58 (SEQ ID NO:113) of WO2016 / 061142: EIVLTQSPATLSLSPGERATLSCKASQDVGTAVAWYLQKPGQSPQLLIYWASTRHTGIPPRFSGSGYGTDFTLTINNIESEDAAYYFCQQYNSYPLTFGQGTKVEIK; SEQ ID NO: 66 (SEQ ID NO: 114) of WO2016 / 061142: DVVMTQSPLSLPVTLGQPASISCKASQDVGTAVAWYQQKPGQAPRLLIYWASTRHTGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPLTFGQGTKVEIK; SEQ ID NO: 74 (SEQ ID NO: 115) of WO2016 / 061142: DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGQAPRLLIYWASTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYNSYPLTFGQGTKVEIK; SEQ ID NO: 82 (SEQ ID NO: 116) of WO2016 / 061142: AIQLTQSPSSLSASVGDRVTITCKASQDVGTAVAWYLQKPGQSPQLLIYWASTRHTGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQYNSYPLTFGQGTKVEIK; SEQ ID NO: 86 (SEQ ID NO: 117) of WO2016 / 061142: EIVLTQSPDFQSVTPKEKVTITCKASQDVGTAVAWYQQKPGQAPRLLIYWASTRHTGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPLTFGQGTKVEIK The light chain comprises an amino acid sequence selected from:

[0061] In one embodiment, the targeting moiety comprises any one of the anti-PD-L1 antibodies disclosed in WO2016 / 022630, the entire contents of which are incorporated herein by reference. In an exemplary embodiment, the antibody or antigen-binding fragment for use in the methods provided herein is set forth in SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46 of WO2016 / 022630: SEQ ID NO: 2 (SEQ ID NO: 118) of WO2016 / 022630: EVKLVESGGGLVKPGGSLKLSCAASGFIFRSYGMSWVRQTPEKRLEWVASISSGGSTYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYDCARGYDSGFAYWGQGTLVTVSE; SEQ ID NO: 6 (SEQ ID NO: 119) of WO2016 / 022630: EVKLVESGGGLVKPGGSLKLSCAASGFTFRSYGMSWVRQTPEKRLEWVASISSGGTTYYPDSVKGRFIISRDNARNILYLQMSSLRSEDTAMYYCAKGYDSGFAYWGQGTLVIVSA; SEQ ID NO: 10 (SEQ ID NO: 120) of WO2016 / 022630: QVQLKQSGPGLVQPSQSLSITCTVSGFSLTTYGVHWVRQSPGKGLEWLGVIWRGVTTDYNAAFMSRLTITKDNSKSQVFFKMNSLQANDTAIYYCARLGFYAMDYWGQGTSVTVSS; SEQ ID NO: 14 (SEQ ID NO: 121) of WO2016 / 022630: QVQLKQSGPGLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVIWSGGVTDYNAAFISRLSISKDNSKSQVFFKMNSLQANDTAIYYCARLGFYAMDYWGQGTSVTVSS; SEQ ID NO: 18 (SEQ ID NO: 122) of WO2016 / 022630: EVKLFESGGGLVQPGGSLKLSCVASGFDFSTYWMHWVRQAPGQGLEWIGQINPDSTTINYAPSLKDRFIISRDNAKNTLFLQMSKVRSEDTALYYCAKPGDYGYDFDCWGQGTTLTVSS; SEQ ID NO: 22 (SEQ ID NO: 123) of WO2016 / 022630: EVQLQESGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGSTYYNPSLKSRISITRDTSKNQYYLQLNSVTTEDTATYYCARSLLWFSTGFAYWGQGTLVTVSA; SEQ ID NO: 26 (SEQ ID NO: 124) of WO2016 / 022630: QVQLKQSGPGLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVIWSGGITDYNAAFKSRLSISKDNSKSQVFFKMNSLQANDTAIYFCARLGFYAMDYWGQGTSVTVSS; SEQ ID NO: 30 (SEQ ID NO: 125) of WO2016 / 022630: EVKLVESGGGLVKPGGSLKLSCAASGFTFRSYGMSWARQIPEKRLEWVASISSGGTTYYLGSVQGRFTISRDNARNILYLQMSSLRSEDTAMYYCARGYDAGFAYWGQGTLVSVSE; SEQ ID NO: 34 (SEQ ID NO: 126) of WO2016 / 022630: EVQLQESGPSLVKPSQTLSLTCSVTGDSITSGYWTWIRKFPGNKLEYMGYISYTGSTYYNPSLKSRISISRDTSKSQYYLQLNSVTTEDTATYYCARQRDWLGFAYWGQGTLVTVSA; SEQ ID NO: 38 (SEQ ID NO: 127) of WO2016 / 022630: EEKLVESGGGLVKPGGSLKLSCAASGFSFSSYGMSWVRQTPEKRLEWVASISSGGSIYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCARGYDAGFAFWGQGTLVTASA; SEQ ID NO: 42 (SEQ ID NO: 128) of WO2016 / 022630: QITLKESGPTLVKPTQTLTLTCTVSGFSLSTYGVHWIRQPPGKALEWLGVIWRGVTTDYNAAFMSRLTITKDNSKNQVVLTMNNMDPVDTATYYCARLGFYAMDYWGQGTLVTVSS; SEQ ID NO: 46 (SEQ ID NO: 129) of WO2016 / 022630: EVQLVESGGGLVKPGGSLRLSCAASGFIFRSYGMSWVRQAPGKGLEWVASISSGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYDCARGYDSGFAYWGQGTLVTVSS and / or a heavy chain comprising an amino acid sequence selected from SEQ ID NOs: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 of WO2016 / 022630: SEQ ID NO: 4 (SEQ ID NO: 130) of WO2016 / 022630: DIVLTQSPASLAVSLGQRATISCRASQSVSTSSSSFMMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEEDTATYYCQHSWEIPYTFGGGTKLEIKR; SEQ ID NO:8 (SEQ ID NO:131) of WO2016 / 022630: DIVLTQSPPSLAVSLGQRATISCRASQSVSTSSSSSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEEDTATYYCQHSWEIPYTFGGGTKLEIK; SEQ ID NO: 12 (SEQ ID NO: 132) of WO2016 / 022630: SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLIYYAANRYTGVPDRFTGSGYGTDFTFTISIVQAEDLAVYFCQQDYTSPYTFGGGTKLEIK; SEQ ID NO: 16 (SEQ ID NO: 133) of WO2016 / 022630: SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDVGWYQQKPGQSPKLLIYYASNRYSGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCQQDYTSPYTFGGGTKLEIK; SEQ ID NO: 20 (SEQ ID NO: 134) of WO2016 / 022630: DVLMTQTPLYLPVSLGDQASISCRSSQIIVHSNANTYLEWFLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK; SEQ ID NO: 24 (SEQ ID NO: 135) of WO2016 / 022630: QIVLTQSPAIMSASPGEKVTLTCSASSSVSSSYLYWNQQKPGSSPKVWIYNTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAASYFCHQWRSYPPTLGAGTKLELK; SEQ ID NO: 28 (SEQ ID NO: 136) of WO2016 / 022630: QIVLTQSPAIMSASPGEKVTMTCSANSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMGAEDAATYYCQQWSSNPWTFGGGTKLEIK; SEQ ID NO: 32 (SEQ ID NO: 137) of WO2016 / 022630: DIVLTQSPASLAVSLGQRATISCRASQSVSTSSYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEEDTATYYCQNSWEIPYTFGGGTKLEIK; SEQ ID NO: 36 (SEQ ID NO: 138) of WO2016 / 022630: DIVMTQTPSSLAVSLGEKVTMSCKSSQSLLYSSNQKNSLAWYQQKPGQSPKLLIYWASNRESGVPDRFTGSSSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK; SEQ ID NO: 40 (SEQ ID NO: 139) of WO2016 / 022630: DIVLTQSPASLAVSLGQRATISCRASQSVSTSSYSYVHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEEDTATYYCQHSWEIPYTFGGGTKLEIK; SEQ ID NO: 44 (SEQ ID NO: 140) of WO2016 / 022630: DIQMTQSPSSLSASVGDRVTITCKASQSVSNDVAWYQQKPGKAPKLLIYYAANRYTGVPDRFSGSGYGTDFTFTISSLQPEDIATYFCQQDYTSPYTFGQGTKLEIK; SEQ ID NO: 48 (SEQ ID NO: 141) of WO2016 / 022630: DIVLTQSPASLAVSPGQRATITCRASQSVSTSSSSFMMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTINPVEANDTANYYCQHSWEIPYTFGQGTKLEIK The light chain comprises an amino acid sequence selected from:

[0062] In one embodiment, the targeting moiety comprises any one of the anti-PD-L1 antibodies disclosed in WO2015 / 112900, the entire contents of which are incorporated herein by reference. In an exemplary embodiment, the antibody or antigen-binding fragment for use in the methods provided herein is selected from the group consisting of SEQ ID NOs: 38, 50, 82, and 86 of WO2015 / 112900: SEQ ID NO: 38 (SEQ ID NO: 142) of WO2015 / 112900: EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSS; SEQ ID NO: 50 (SEQ ID NO: 143) of WO 2015 / 112900: EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKNRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRWTTGTGAYWGQGTTVTVSS; SEQ ID NO: 82 (SEQ ID NO: 144) of WO 2015 / 112900: QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYWMHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKNRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRWTTGTGAYWGQGTTVTVSS; SEQ ID NO: 86 (SEQ ID NO: 145) of WO 2015 / 112900: EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQAPGQGLEWMGNIYPGTGGSNFDEKFKNRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRWTTGTGAYWGQGTTVTVSS and / or a heavy chain comprising an amino acid sequence selected from SEQ ID NOs: 42, 46, 54, 58, 62, 66, 70, 74, and 78 of WO2015 / 112900: SEQ ID NO: 42 (SEQ ID NO: 146) of WO2015 / 112900: EIVLTQSPATLLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQNDYSYPYTFGQGTKVEIK; SEQ ID NO: 46 (SEQ ID NO: 147) of WO 2015 / 112900: DIQMTQSPSSLSASVGDRVTITCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGIPPRFSGSGYGTDFTLTINNIESEDAAYYFCQNDYSYPYTFGQGTKVEIK; SEQ ID NO: 54 (SEQ ID NO: 148) of WO 2015 / 112900: EIVLTQSPATLLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQNDYSYPYTFGQGTKVEIK; SEQ ID NO: 58 (SEQ ID NO: 149) of WO 2015 / 112900: DIVMTQTPLSLPVTPGEPASISCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK; SEQ ID NO: 62 (SEQ ID NO: 150) of WO 2015 / 112900: EIVLTQSPATLLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK; SEQ ID NO: 66 (SEQ ID NO: 151) of WO 2015 / 112900: EIVLTQSPDFQSVTPKEKVTITCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK; SEQ ID NO: 70 (SEQ ID NO: 152) of WO 2015 / 112900: EIVLTQSPATLLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK; SEQ ID NO: 74 (SEQ ID NO: 153) of WO 2015 / 112900: DIQMTQSPSSLSASVGDRVTITCKSSQSLLDSGNQKNFLTWYLQKPGQSPQLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK; SEQ ID NO: 78 (SEQ ID NO: 154) of WO 2015 / 112900: DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSGNQKNFLTWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK The light chain comprises an amino acid sequence selected from:

[0063] In one embodiment, the targeting moiety comprises any one of the anti-PD-L1 antibodies disclosed in WO 2010 / 077634, and US8,217,149, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, the anti-PD-L1 antibody or antigen-binding fragment thereof for use in the methods provided herein is: SEQ ID NO: 20 (SEQ ID NO: 155) of WO 2010 / 077634: EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSA and / or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 21 (SEQ ID NO: 156) of WO 2010 / 077634: DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKR The light chain variable region comprises the amino acid sequence of:

[0064] In one embodiment, the targeting moiety comprises any one of the anti-PD-L1 antibodies obtained from hybridomas accessible under CNCM deposit numbers CNCM I-4122, CNCM I-4080 and CNCM I-4081, as disclosed in US 20120039906, the entire disclosure of which is incorporated herein by reference.

[0065] In one embodiment, the targeting moiety comprises a VHH directed against PD-L1, e.g., as disclosed in US 8,907,065 and WO 2008 / 071447, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, the VHH against PD-L1 is set forth in SEQ ID NOs: 394-399 of US 8,907,065: SEQ ID NO: 394 of US 8,907,065 (SEQ ID NO: 157): EVQLVESGGGLVQPGGSLRLSCAASGFTLDYYAIGWFRQAPGKEREWASSISSSDGSTYYADSVKGRFTISRDNAKNTVFLQMNSLKPEDTAVYSCAASQAPITIATMMKPFYDYWGQGTQVTVSS; SEQ ID NO: 395 of US 8,907,065 (SEQ ID NO: 158): EVQLVESGGGLVQPGGSLRLSCAASGFTLDYYAKCWFRQAPGKEREWVSCISSSDGSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYFCAARHGGPLTVEYFFDYWGQGTQVTVSS; SEQ ID NO: 396 of US 8,907,065 (SEQ ID NO: 159): EVQLVESGGGLVQPGGSLRLSCAASGFTFDYYAIGWFRQAPGKAREGVSCISGGDNSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCATGGWKYCSGYDPEYIYWGQGTQVTVSS; SEQ ID NO: 397 of US 8,907,065 (SEQ ID NO: 160): EVQLVESGGGLVQAGGSLRLLSCAASGSTFSQYDVGWYRQAPGKQRELVAFSSSGGRTIYPDSVKGRFTFSRDNTKNTVYLQMTSLKPEDTAVYYCKIDWYLNSYWGQGTQVTVSS; SEQ ID NO: 398 of US 8,907,065 (SEQ ID NO: 161): EVQLVESGGGLVQAGGSLRLSCAASGVDASNSAMGWYRQAPGKQREWVARITGGGLIAYTDSVKGRFTISRDNAKSTVYLQMNSLEPEDTAVYYCNTINSRDGWGQGTQVTVSS; SEQ ID NO: 399 of US 8,907,065 (SEQ ID NO: 162): EVQLVESGGGLVQAGGSLTISCAASGITFSDSIVSWYRRARGKQREWVAGISNGGTTKYAESVLGRFTISRDNAKNNVYLQMNGLNPEDTAVYLCKVRQYWGQGTQVTVSS Includes.

[0066] In various embodiments, the chimeric proteins of the invention have one targeting moiety directed against PD-L2. In some embodiments, the chimeric protein comprises one targeting moiety that selectively binds a PD-L2 polypeptide. In some embodiments, the chimeric protein comprises an antibody, an antibody derivative or form, a peptide or polypeptide, or a fusion protein that selectively binds a PD-L2 polypeptide.

[0067] In one embodiment, the targeting moiety comprises a VHH directed against PD-L2, e.g., as disclosed in US 8,907,065 and WO 2008 / 071447, the entire disclosures of which are incorporated herein by reference. In an exemplary embodiment, the VHH directed against PD-1 is set forth in SEQ ID NOs: 449-455 of US 8,907,065: SEQ ID NO: 449 of US 8,907,065 (SEQ ID NO: 163): EVQLVESGGGLVQAGGSLRLLSCAASESTVLINAMGWYRQAPGKQRELVASISSGGSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADVYPQDYGLGYVEGKVYYGHDYWGTGTLVTVSS; SEQ ID NO: 450 of US 8,907,065 (SEQ ID NO: 164): EVQLVESGGGLVQAGGSLRLSCAASGSTFSNYVSNYAMGWGRQAPGTQRELVASISNGDTTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCFEHQVAGLTWGQGTQVTVSS; SEQ ID NO: 451 (SEQ ID NO: 165) of US 8,907,065: EVQLVESGGGLVQAGGSLRLSCVASGXALKIXVMGWYRQAPGKQRELVAAITSGGRTNYSDSVKGRFTISGDNAXNTVYLQMNSLKSEDTAVYYCREWNSGYPPVDYWGQGTQVTVSS; SEQ ID NO: 452 of US 8,907,065 (SEQ ID NO: 166): EVQLVESGGGLVQAGGSLRLSCAASGRTFSSGTMGWFRRAPGKEREFVASIPWSGGRTYYADSVKDRFTISRDNAQNTVFLQMNSLKPEDTAVYYCAFKERSTGWDFASWGQGIQVTVSS; SEQ ID NO: 453 of US 8,907,065 (SEQ ID NO: 167): EVQLVESGGGLVQTGGSLRLSCAASGFTLDYYGIGWFRQAPGKEREGVSFISGSDGSTYYAESVKGRFTISRDKAKNTVYLQMNSLKPEDTAVYYCAADPWGPPSIATMTSYEYKHWGQGTQVTVSS; SEQ ID NO: 454 of US 8,907,065 (SEQ ID NO: 168): EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYTMIWLRRAPGKGFEWVSTIDKDGNTNYVDSVKGRFAVSRDNTKNTLYLQMNSLKPEDTAMYYCTKHGSSARGQGTRVTVSS; SEQ ID NO: 455 of US 8,907,065 (SEQ ID NO: 169): EVQLVESGGGLVEPGGSLRLSCVASGTFFSSYDMSWVRQAPGKGLEWVSTINSGGGITYRGSVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCENGGSSYRRGQGTQVTVSS Includes.

[0068] In one embodiment, the targeting moiety comprises any one of the anti-PD-L2 antibodies disclosed in US2011 / 0271358 and WO2010 / 036959, the entire contents of which are incorporated herein by reference. In an exemplary embodiment, the antibody or antigen-binding fragment thereof for use in the methods provided herein is set forth in SEQ ID NOs: 43-47 of US2011 / 0271358: SEQ ID NO: 43 of US2011 / 0271358 (SEQ ID NO: 170): QVQLVQSGAELKKPGASVKMSCKASGYTFTGYTMHWVKQAPGQGLEWIGYINPRSGYTEYNQKFKDRTTLTADKSTSTAYMELSSLRSEDSAVYYCARPWFAYWGQGTLVTVSS; SEQ ID NO: 44 of US2011 / 0271358 (SEQ ID NO: 171): QVQLVQSGAEVKKPGASVKMSCKASGYTFTGYTMHWVKQAPGQGLEWIGYINPRSGYTEYNQKFKDRTTLTADKSTSTAYMELSSLRSEDTAVYYCARPWFAYWGQGTLVTVSS; SEQ ID NO: 45 of US2011 / 0271358 (SEQ ID NO: 172): QVQLVQSGAEVKKPGASVKMSCKASGYTFTGYTMHWVRQAPGQGLEWIGYINPRSGYTEYNQKFKDRTTLTADKSTSTAYMELSSLRSEDTAVYYCARPWFAYWGQGTLVTVSS; SEQ ID NO: 46 of US2011 / 0271358 (SEQ ID NO: 173): QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYTMHWVRQAPGQGLEWIGYINPRSGYTEYNQKFKDRTTLTADKSTSTAYMELSSLRSEDTAVYYCARPWFAYWGQGTLVTVSS; SEQ ID NO: 47 of US2011 / 0271358 (SEQ ID NO: 174): QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYTMHWVRQAPGQGLEWIGYINPRSGYTEYNQKFKDRTTITADKSTSTAYMELSSLRSEDTAVYYCARPWFAYWGQGTLVTVSS and / or a heavy chain comprising an amino acid sequence selected from SEQ ID NOs: 48-51 of US2011 / 0271358: SEQ ID NO: 48 of US2011 / 0271358 (SEQ ID NO: 175): DIVMTQSPASLTVTPGEKVTITCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPLTFGQGTKLEIK; SEQ ID NO: 49 of US2011 / 0271358 (SEQ ID NO: 176): DIVMTQSPASLSVTPGEKVTITCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPLTFGQGTKLEIK; SEQ ID NO:50 of US2011 / 0271358 (SEQ ID NO:177): DIVMTQSPAFLSVTPGEKVTITCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPLTFGQGTKLEIK; SEQ ID NO:51 of US2011 / 0271358 (SEQ ID NO:178): DIVMTQSPAFLSVTPGEKVTITCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPLTFGQGTKLEIK The light chain comprises an amino acid sequence selected from:

[0069] In various embodiments, the targeting moieties of the invention are capable of binding to any of the sequences disclosed herein at least about 60%, at least about 61%, at least about 62%, at least about 63%, at least about 64%, at least about 65%, at least about 66%, at least about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100%, at least about 101%, at least about 102%, at least about 103%, at least about 104%, at least about 105%, at least about 106%, at least about 107%, at least about 108%, at least about 109%, at least about 110%, at least about 111%, at least about 112%, at least about 113%, at least about 114%, at least about 115%, at least about 116%, at least about 117%, at least about 118%, at least about 119%, at least about 120%, at least about 121%, at least about 122%, at least about 123%, at least about 124%, at least about 125 at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, or about 98%, at least about 99%, or 100% identical to any of the sequences disclosed herein (e.g., about 60%, or about 61%, or about 62%, or about 63%, or about 64%, or about 65%, or about 66%, or about 67%, or about 68%, or about 69%, or about 70%, or about 71%, or about 72%, or about 73%, or about 74%, or about 75%, or about 76%, or about 77%, or about 78%, or about 79%, or about 80%, or about 82%, or about 84%, or about 86%, or about 88%, or about 89%, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, or about 10 ... In some embodiments, the PD-1, PD-L1, and / or PD-L2 targeting sequences may comprise sequences that target PD-1, PD-L1, and / or PD-L2 that are approximately 0%, or about 81%, or about 82%, or about 83%, or about 84%, or about 85%, or about 86%, or about 87%, or about 88%, or about 89%, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, or about 100% sequence identity to the PD-1, PD-L1, and / or PD-L2 targeting sequences.

[0070] In various embodiments, the targeting moieties of the invention may comprise any combination of heavy chain, light chain, heavy chain variable region, light chain variable region, complementarity determining region (CDR), and framework region sequences that target PD-1, PD-L1, and / or PD-L2 as disclosed herein.

[0071] Additional antibodies, antibody derivatives or formats, peptides or polypeptides, or fusion proteins that selectively bind or target PD-1, PD-L1, and / or PD-L2 are described in WO 2011 / 066389, US 2008 / 0025980, US 2013 / 0034559, US 8,779,108, US 2014 / 0356353, US 8,609,089, US 2010 / 028330, US 2012 / 0114649, WO 2010 / 027827, WO 2011, / 066342, US 8,907,065, WO 2016 / 062722, WO 2009 / 101611, WO2010 / 027827, WO 2011 / 066342, WO 2007 / 005874, WO 2001 / 014556, US2011 / 0271358, WO 2010 / 036959, WO 2010 / 077634, US 8,217,149, US 2012 / 0039906, WO 2012 / 145493, US 2011 / 0318373, US Patent 8,779,108, US 20140044738, WO 2009 / 089149, WO 2007 / 00587, WO 2016061142, WO 2016,02263, WO 2010 / 077634, and WO 2015 / 112900.

[0072] Modified Signal Transduction Agents In one aspect, the present invention provides a chimeric protein comprising a signaling agent (e.g., an immunomodulatory agent). In various embodiments, the signaling agent is modified to have a reduced activity. In some embodiments, the signaling agent is modified to have a reduced affinity for one or more of its receptors, which allows for attenuation of the activity of the chimeric protein and / or prevents non-specific signaling or undesired sequestration. In various embodiments, the activity of the modified signaling agent is restored in the context of a chimeric protein that further comprises a targeting moiety that targets a specific cell type. In particular, the activity of the modified signaling agent is restored to target cells but not to non-target cells. Thus, in various embodiments, the chimeric proteins of the present invention provide therapeutic advantages such as enhanced specificity and efficacy in target cells, as well as reduced side effects, including lower systemic toxicity.

[0073] In various embodiments, the signaling agent is selected from an immunomodulatory agent, such as modified forms of one or more of the following: interleukins, interferons, and tumor necrosis factors.

[0074] In some embodiments, the signaling agent is a modified form of an interleukin, including, for example, IL-1; IL-2; IL-3; IL-4; IL-5; IL-6; IL-7; IL-8; IL-9; IL-10; IL-11; IL-12; IL-13; IL-14; IL-15; IL-16; IL-17; IL-18; IL-19; IL-20; IL-21; IL-22; IL-23; IL-24; IL-25; IL-26; IL-27; IL-28; IL-29; IL-30; IL-31; IL-32; IL-33; IL-35; IL-36, or a fragment, variant, analog, or family member thereof.

[0075] In some embodiments, the signaling agent is a modified type of interferon, such as type I, II, and III interferons. Exemplary interferons include, for example, interferon-α-1, 2, 4, 5, 6, 7, 8, 10, 13, 14, 16, 17, and 21, interferon-β and interferon-γ, interferon-κ, interferon-ε, interferon-τ, and interferon-ω.

[0076] In some embodiments, the signaling agent is a modified form of tumor necrosis factor (TNF) or the TNF family of proteins, including, but not limited to, TNF-α, TNF-β, LT-β, ​​CD40L, CD27L, CD30L, FASL, 4-1BBL, OX40L, and TRAIL.

[0077] In various embodiments, the signaling agent is a modified (e.g., mutant) form of a signaling agent having one or more mutations. In various embodiments, the mutations allow the modified signaling agent to have one or more attenuated activities, such as one or more decreased binding affinity, decreased intrinsic activity, and decreased specific biological activity, compared to the unmodified or unmutated, i.e., wild-type, signaling agent (e.g., comparing the same signaling agent in wild-type vs. modified (e.g., mutant) form). In some embodiments, the mutations that attenuate or reduce binding or affinity include mutations that substantially reduce or eliminate binding or activity. In some embodiments, the mutations that attenuate or reduce binding or affinity are different from mutations that substantially reduce or eliminate binding or activity. As a result, in various embodiments, the mutations allow the signaling agent to be safer, e.g., have reduced systemic toxicity, reduced side effects, and reduced off-target effects, compared to the unmutated, i.e., wild-type, signaling agent (e.g., comparing the same signaling agent in wild-type vs. modified (e.g., mutant) form). As described herein, a signal transduction agent may have improved safety due to one or more modifications, such as mutations. In various embodiments, improved safety means that the chimeric protein of the present invention provides lower toxicity (e.g., systemic toxicity and / or tissue / organ-related toxicity); and / or reduced or substantially eliminated side effects; and / or increased tolerance, reduced or substantially eliminated adverse events; and / or reduced or substantially eliminated off-target effects; and / or increased therapeutic window.

[0078] In various embodiments, the signaling agent is modified to have one or more mutations that reduce its binding affinity or activity to one or more of its receptors. In some embodiments, the signaling agent is modified to have one or more mutations that substantially reduce or eliminate its binding affinity or activity to the receptor. In some embodiments, the activity provided by the wild-type signaling agent is agonism at the receptor (e.g., activating a cellular effect at the site of therapy). For example, the wild-type signaling agent can activate its receptor. In such embodiments, the mutation results in a modified signaling agent with reduced or eliminated activating activity at the receptor. For example, the mutation can also result in a modified signaling agent that delivers a reduced activation signal to the target cell, or the activation signal can be eliminated. In some embodiments, the activity provided by the wild-type signaling agent is antagonism at the receptor (e.g., blocking or attenuating a cellular effect at the site of therapy). For example, the wild-type signaling agent can antagonize or inhibit the receptor. In these embodiments, the mutation results in a modified signaling agent with reduced or eliminated antagonizing activity at the receptor. For example, mutation can result in a modified signaling agent that delivers a reduced inhibitory signal to target cells, or the inhibitory signal can be eliminated.In various embodiments, the signaling agent is antagonistic due to one or more mutations, for example, an agonistic signaling agent is converted into an antagonistic signaling agent (e.g., as described in WO 2015 / 007520, the entire contents of which are incorporated herein), and such converted signaling agent optionally also has one or more mutations that reduce the binding affinity or activity to one or more of its receptors, or substantially reduce or eliminate the binding affinity or activity to one or more of its receptors.In some embodiments, the reduced affinity or activity at the receptor can be restored by attachment with a targeting moiety.In other embodiments, the reduced affinity or activity at a receptor is not substantially restorable by attachment to a targeting moiety.

[0079] In various embodiments, the chimeric protein of the present invention reduces off-target effects because the signaling agent has a mutation that weakens or eliminates the binding affinity or activity at the receptor. In various embodiments, this reduction in side effects is observed, for example, compared to wild-type signaling agents. In various embodiments, the signaling agent is active on the target cell because the targeting moiety compensates for the missing / insufficient binding (for example, without limitation, and / or avidity) required for substantial activation. In various embodiments, the modified signaling agent is substantially inactive on the way to the site of therapeutic activity and has substantially its effect on the specifically targeted cell type, which greatly reduces undesirable side effects.

[0080] In some embodiments, the signaling agent may contain one or more mutations that attenuate or reduce binding or affinity to one receptor (i.e., a therapeutic receptor) and one or more mutations that substantially reduce or eliminate binding or activity at a second receptor. In such embodiments, these mutations may be at the same position or at different positions (i.e., the same mutation or multiple mutations). In some embodiments, the mutation(s) that reduce binding and / or activity at one receptor are different from the mutation(s) that substantially reduce or eliminate binding and / or activity at another receptor. In some embodiments, the mutation(s) that reduce binding and / or activity at one receptor are the same as the mutation(s) that substantially reduce or eliminate binding and / or activity at another receptor. In some embodiments, the chimeric proteins of the present invention have modified signaling agents that have both mutations that attenuate binding and / or activity at a therapeutic receptor, thus allowing for a more controlled on-target therapeutic effect (e.g., compared to a wild-type signaling agent), and mutations that substantially reduce or eliminate binding and / or activity at another receptor, thus reducing side effects (e.g., compared to a wild-type signaling agent).

[0081] In some embodiments, the substantial reduction or elimination of binding or activity is not substantially reversible by the targeting moiety. In some embodiments, the substantial reduction or elimination of binding or activity is substantially reversible by the targeting moiety. In various embodiments, the substantial reduction or elimination of binding or activity at the second receptor can also prevent adverse effects mediated by other receptors. Alternatively, or in addition, the substantial reduction or elimination of binding or activity at other receptors causes an improvement in the therapeutic effect because there is reduced or eliminated sequestration of the therapeutic chimeric protein away from the therapeutic action site. For example, in some embodiments, this obviates the need for high doses of the chimeric protein of the present invention to compensate for losses at other receptors. Such ability to reduce the dose further provides a lower probability of side effects.

[0082] In various embodiments, a modified signaling agent is one in which the signaling agent has reduced, substantially reduced, or eliminated affinity, e.g., binding (e.g., K D ) and / or activation (e.g., when the modulating signal transduction agent is an agonist of that receptor, e.g., K A and / or E.C. 50 ) and / or inhibition (e.g., when the modulating signal transduction agent is an antagonist of that receptor, e.g., K I and / or I.C. 50 In various embodiments, the signaling agent contains one or more mutations that cause the signaling agent to have a reduced affinity for the receptor (which can be measured as agonism or antagonism). In various embodiments, the reduced affinity of the signaling agent at the receptor allows for attenuated activity (including agonism or antagonism). In such embodiments, the modified signaling agent has about 1%, or about 3%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 10%-20%, about 20%-40%, about 50%, about 40%-60%, about 60%-80%, about 80%-100% of the affinity for the receptor as compared to the wild-type signaling agent. In some embodiments, the binding affinity is at least about 2-fold lower, about 3-fold lower, about 4-fold lower, about 5-fold lower, about 6-fold lower, about 7-fold lower, about 8-fold lower, about 9-fold lower, at least about 10-fold lower, at least about 15-fold lower, at least about 20-fold lower, at least about 25-fold lower, at least about 30-fold lower, at least about 35-fold lower, at least about 40-fold lower, at least about 45-fold lower, at least about 50-fold lower, at least about 100-fold lower, at least about 150-fold lower, or about 10-50-fold lower, about 50-100-fold lower, about 100-150-fold lower, about 150-200-fold lower, or more than 200-fold lower, as compared to a wild-type signaling agent.

[0083] In embodiments where the chimeric protein has mutations that reduce binding at one receptor and substantially reduce or eliminate binding at a second receptor, the reduced or decreased binding affinity of the modified signaling agent to one receptor is less than the substantial reduction or elimination of affinity to the other receptor. In some embodiments, the reduced or decreased binding affinity of the modified signaling agent to one receptor is less than the substantial reduction or elimination of affinity to the other receptor by about 1%, or by about 3%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95%. In various embodiments, the substantial reduction or elimination refers to a greater reduction in binding affinity and / or activity than the reduced or decreased binding affinity.

[0084] In various embodiments, the modified signaling agent comprises one or more mutations that reduce the intrinsic activity of the signaling agent to about 75%, or about 70%, or about 60%, or about 50%, or about 40%, or about 30%, or about 25%, or about 20%, or about 10%, or about 5%, or about 3%, or about 1%, for example, compared to a wild-type signaling agent.

[0085] In some embodiments, the modified signaling agent comprises one or more mutations that allow the signaling agent to have a reduced affinity for its receptor that is lower than the binding affinity of the targeting moiety for its receptor. In some embodiments, this difference in binding affinity is between the signaling agent / receptor and the targeting moiety / receptor on the same cell. In some embodiments, this difference in binding affinity allows the signaling agent, e.g., the mutant signaling agent, to have a localized on-target effect and minimize the off-target effect that underlies the side effects observed with wild-type signaling agents. In some embodiments, this binding affinity is at least about 2-fold, or at least about 5-fold, or at least about 10-fold, or at least about 15-fold, or at least about 25-fold, or at least about 50-fold, or at least about 100-fold, or at least about 150-fold.

[0086] Receptor binding activity can be measured using methods known in the art.For example, affinity and / or avidity can be evaluated by Scatchard plot analysis and computer fitting of binding data (e.g., Scatchard, 1949), or by refractive index interferometry under flow-through conditions as described by Brecht et al. (1993), the entire contents of all of which are incorporated herein by reference.

[0087] The amino acid sequences of the wild-type signaling agents described herein are known in the art. Thus, in various embodiments, the modified signaling agent is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 100%, or at least about 150%, or at least about 160%, or at least about 170%, or at least about 180%, or at least about 190%, or at least about 200%, or at least about 210%, or at least about 220%, or at least about 230%, or at least about 240%, or at least about 250%, or at least about 260%, or at least about 270%, or at least about 280%, or at least about 290%, or at least about 300%, or at least about 310%, or at least about 320%, or at least about 330%, or at least about 340%, or at least about 350%, or at least about 360%, or at least about 370%, or at least about 380%, or at least about 390%, or at least about 400%, or at least about 410%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity (e.g., about 60%, or about 61%, or about 62%, or about 63%, or about 64%, or about 65%, or about 66%, or about 67%, or about 68%, or about 69%, or about 70%, or about 71%, or about 72%, or about 73%, or about 74%, or about 75%, or about 76%, or about 77%, or about 78%, or about 79%, or about 80%, or about 81%, or about 82%, or about 83%, or about 84%, or about 85%, or about 86%, or about 87%, or about 88%, or about 89%, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% sequence identity (e.g., about 60%, or about 61%, or about 62%, or about 63%, or about 64%, or about 65%, or about 66%, or about 67%, or about 68%, or about 69%, or about 70%, or about 71%, or about 72%, or about 73%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, or about 90 %, or about 74%, or about 75%, or about 76%, or about 77%, or about 78%, or about 79%, or about 80%, or about 81%, or about 82%, or about 83%, or about 84%, or about 85%, or about 86%, or about 87%, or about 88%, or about 89%, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% sequence identity to the amino acid sequence.

[0088] In various embodiments, the modified signaling agent is hybridized to any of the sequences disclosed herein with at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%. , or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity (e.g., about 60%, or about 61%, or about 62%, or about 63%, or about 64%, or about 65%, or about 66%, or about 67%, or about 68%, or about 69%, or about 70%, or about 71%, or about 72%, or about 73%, or comprises an amino acid sequence having about 74%, or about 75%, or about 76%, or about 77%, or about 78%, or about 79%, or about 80%, or about 81%, or about 82%, or about 83%, or about 84%, or about 85%, or about 86%, or about 87%, or about 88%, or about 89%, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% sequence identity.

[0089] In various embodiments, the modified signaling agent comprises an amino acid sequence having one or more amino acid mutations. In some embodiments, the one or more mutations may be independently selected from substitutions, insertions, deletions, and truncations.

[0090] In some embodiments, the amino acid mutations are amino acid substitutions, which may include conservative and / or non-conservative substitutions.

[0091] "Conservative substitutions" may be made, for example, on the basis of similarity in polarity, charge, size, solubility, hydrophobicity, hydrophilicity, and / or amphipathicity of the amino acid residues involved. The 20 naturally occurring amino acids can be grouped into six standard amino acid groups: (1) hydrophobic: Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr; Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that affect chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe.

[0092] As used herein, "conservative substitution" is defined as the replacement of an amino acid with another amino acid that is listed in the same group of the six standard amino acid groups shown above. For example, the replacement of Asp with Glu will retain one negative charge in the thus modified polypeptide. Furthermore, glycine and proline may be substituted for each other based on their ability to disrupt α-helix.

[0093] As used herein, a "non-conservative substitution" is defined as the replacement of an amino acid with another amino acid listed in a different group of the six standard amino acid groups (1) to (6) shown above.

[0094] In various embodiments, substitutions may also include non-classical amino acids (e.g., selenocysteine, pyrrolidine, N-formylmethionine β-alanine, GABA and δ-aminolevulinic acid, 4-aminobenzoic acid (PABA), D-isomers of common amino acids, 2,4-diaminobutyric acid, α-aminoisobutyric acid, 4-aminobutyric acid, Abu, 2-aminobutyric acid, γ-Abu, ε-Ahx, 6-aminohexanoic acid, Aib, 2-aminoisobutyric acid, 3-aminopropionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β-alanine, fluoroamino acids, designer amino acids such as β-methyl amino acids, Cα-methyl amino acids, Nα-methyl amino acids, and amino acid analogs in general).

[0095] As described herein, the modified signaling agent has a mutation that affects affinity and / or activity at one or more receptors. In various embodiments, there is a decreased affinity and / or activity at a therapeutic receptor, e.g., a receptor that mediates a desired therapeutic effect (e.g., agonism or antagonism). In various embodiments, the modified signaling agent has a mutation that substantially reduces or eliminates (e.g., as a result of disruption of binding) affinity and / or activity at a receptor, e.g., a receptor that does not mediate a desired therapeutic effect. Any modified signaling agent, e.g., a receptor for one of the cytokines, growth factors, and hormones described herein, is known in the art.

[0096] Exemplary mutations that provide reduced affinity and / or activity (e.g., agonistic) at a receptor can be found in WO 2013 / 107791 (e.g., for interferons), WO 2015 / 0007542 (e.g., for interleukins), and WO 2015 / 007903 (for TNF), each of which is incorporated herein in its entirety. Exemplary mutations that provide reduced affinity and / or activity (e.g., antagonistic) at a therapeutic receptor can be found in WO2015 / 007520, each of which is incorporated herein in its entirety.

[0097] In some embodiments, the modified signaling agent contains one or more mutations that cause the signaling agent to have reduced affinity and / or activity for type I cytokine receptors, type II cytokine receptors, and receptors of the tumor necrosis factor receptor (TNFR) superfamily.

[0098] In various embodiments, the receptor for the signal transduction agent is a type I cytokine receptor. Type I cytokine receptors are known in the art and include, but are not limited to, receptors for IL2 (beta subunit), IL3, IL4, IL5, IL6, IL7, IL9, IL11, IL12, GM-CSF, G-CSF, LIF, CNTF, and also receptors for thrombopoietin (TPO), prolactin, and growth hormone. Exemplary type I cytokine receptors include, but are not limited to, GM-CSF receptor, G-CSF receptor, LIF receptor, CNTF receptor, TPO receptor, and type I IL receptor.

[0099] In various embodiments, the receptor for signal transduction agent is type II cytokine receptor. Type II cytokine receptor is a multimeric receptor composed of heterogeneous subunits, and is mainly a receptor for interferon. This receptor family includes, but is not limited to, receptor for interferon-α, interferon-β and interferon-γ, IL10, IL22, and tissue factor. Exemplary type II cytokine receptors include, but are not limited to, IFN-α receptor (e.g., IFNAR1 and IFNAR2), IFN-β receptor, IFN-γ receptor (e.g., IFNGR1 and IFNGR2), and type II IL receptor.

[0100] In various embodiments, the receptor for the signaling agent is a TNFR family member. Tumor necrosis factor receptor (TNFR) family members share a cysteine-rich domain (CRD) formed by three disulfide bonds around a core motif of CXXCXXC, generating an extended molecule. Exemplary tumor necrosis factor receptor family members are: CDl 20a (TNFRSFlA), CD 120b (TNFRSFlB), lymphotoxin beta receptor (LTBR, ​​TNFRSF3), CD 134 (TNFRSF4), CD40 (CD40, TNFRSF5), FAS (FAS, TNFRSF6), TNFRSF6B (TNFRSF6B), CD27 (CD27, TNFRSF7), CD30 (TNFRSF8), CD137 (TNFRSF9), TNFRSFlOA (TNFRSFlOA), TNFRSFlOB, (TNFRSFlOB), TNFRSFlOC (TNFRSFlOC), TNFRSFlOD (TNFRSFlOD), RANK (TNFRSFI lA), osteoprotegerin (TNFRSFl IB), TNFRSF12A (TNFRSF12A), TNFRSF13B (TNFRSF13B), TNFRSF13C (TNFRSF13C), TNFRSF14 (TNFRSF14), nerve growth factor receptor (NGFR, TNFRSF16), TNFRSF17 (TNFRSF17), TNFRSF18 (TNFRSF18), TNFRSF19 (TNFRSF19), TNFRSF21 (TNFRSF21), and TNFRSF25 (TNFRSF25).

[0101] In one embodiment, the modified signal transduction agent is interferon alpha. In such embodiments, the modified IFN-alpha agent has reduced affinity and / or activity for the IFN-alpha / beta receptor (IFNAR), i.e., the IFNAR1 and / or IFNAR2 chains. In some embodiments, the modified IFN-alpha agent has substantially reduced or eliminated affinity and / or activity for the IFN-alpha / beta receptor (IFNAR), i.e., the IFNAR1 and / or IFNAR2 chains.

[0102] Mutant forms of interferon alpha, such as IFN-α2, are known to those of skill in the art. In an exemplary embodiment, the modified signaling agent is: IFN-α2a (SEQ ID NO: 179): CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE It is an allelic type IFN-α2a having the amino acid sequence:

[0103] In an exemplary embodiment, the modified signaling agent is: IFN-α2b (SEQ ID NO: 180): CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE The allele is IFN-α2b, which has the amino acid sequence (which differs from IFN-α2a at amino acid position 23).

[0104] In some embodiments, the IFN-α2 mutant (IFN-α2a or IFN-α2b) is mutated at one or more amino acids at positions 144-154, such as at amino acid positions 148, 149 and / or 153. In some embodiments, the IFN-α2 mutant comprises one or more mutations selected from L153A, R149A, and M148A. Such mutants are described, for example, in WO2013 / 107791 and Piehler et al. (2000) J. Biol. Chem, 275:40425-33, the entire contents of which are incorporated herein by reference.

[0105] In some embodiments, the IFN-α2 mutant has reduced affinity and / or activity for IFNAR1. In some embodiments, the IFN-α2 mutant comprises one or more mutations selected from F64A, N65A, T69A, L80A, Y85A, and Y89A, as described in WO2010 / 030671, the entire contents of which are incorporated herein by reference.

[0106] In some embodiments, the IFN-α2 mutant comprises one or more mutations selected from K133A, R144A, R149A, and L153A, as described in WO2008 / 124086, the entire contents of which are incorporated herein by reference.

[0107] In some embodiments, the IFN-α2 mutant comprises a mutation at position R120. In some embodiments, the IFN-α2 mutant comprises one or more mutations selected from R120E and R120E / K121E, as described in WO2015 / 007520 and WO2010 / 030671, the entire contents of which are incorporated herein by reference. In such embodiments, the IFN-α2 mutant antagonizes wild-type IFN-α2 activity. In such embodiments, the mutant IFN-α2 has reduced affinity and / or activity for IFNAR1, while affinity and / or activity for IFNR2 is retained.

[0108] In some embodiments, the IFN-α2 mutant comprises (1) one or more mutations selected from R120E and R120E / K121E, which produce antagonistic effects, and (2) one or more mutations selected from K133A, R144A, R149A, and L153A, which, while not wishing to be bound by theory, allow for attenuated effects, for example, on IFNAR2. In some embodiments, the IFN-α2 mutant comprises an R120E mutation and either R149A or L153A. In one embodiment, the human IFN-α2 mutant comprises R120E and L153A.

[0109] In some embodiments, the human IFN-α2 mutant comprises one or more mutations selected from L15A, A19W, R22A, R23A, L26A, F27A, L30A, L30V, K31A, D32A, R33K, R33A, R33Q, H34A, D35A, Q40A, D114R, L117A, R120A, R125A, K134A, R144A, A145G, A145M, M148A, R149A, S152A, L153A, and N156A, as disclosed in WO2013 / 059885, the entire disclosure of which is incorporated herein by reference. In some embodiments, the human IFN-α2 mutant comprises mutations H57Y, E58N, Q61S, and / or L30A, as disclosed in WO2013 / 059885. In some embodiments, the human IFN-α2 mutant comprises mutations H57Y, E58N, Q61S, and / or R33A, as disclosed in WO2013 / 059885. In some embodiments, the human IFN-α2 mutant comprises mutations H57Y, E58N, Q61S, and / or M148A, as disclosed in WO2013 / 059885. In some embodiments, the human IFN-α2 mutant comprises mutations H57Y, E58N, Q61S, and / or L153A, as disclosed in WO2013 / 059885. In some embodiments, the human IFN-α2 mutant comprises the mutations N65A, L80A, Y85A, and / or Y89A, as disclosed in WO2013 / 059885. In some embodiments, the human IFN-α2 mutant comprises the mutations N65A, L80A, Y85A, Y89A, and / or D114A, as disclosed in WO2013 / 059885.

[0110] In one embodiment, the modified signal transduction agent is interferon beta. In such embodiments, the modified interferon beta agent has reduced affinity and / or activity for the IFN-α / β receptor (IFNAR), i.e., the IFNAR1 and / or IFNAR2 chains. In some embodiments, the modified interferon beta agent has substantially reduced or eliminated affinity and / or activity for the IFN-α / β receptor (IFNAR), i.e., the IFNAR1 and / or IFNAR2 chains.

[0111] In one embodiment, the modified signal transduction agent is interferon gamma. In such an embodiment, the modified interferon gamma agent has a reduced affinity and / or activity for interferon gamma receptor (IFNGR), i.e., IFNGR1 and IFNGR2 chains. In some embodiments, the modified interferon gamma agent has a substantially reduced or eliminated affinity and / or activity for interferon gamma receptor (IFNGR), i.e., IFNGR1 and IFNGR2 chains.

[0112] In one embodiment, the modulating signal transduction agent is TNF-α. TNF is a pleiotropic cytokine with many diverse functions, including regulating cell proliferation, differentiation, apoptosis, tumor development, viral replication, autoimmunity, immune cell function and trafficking, inflammation, and septic shock. TNF binds to two distinct membrane receptors on target cells: TNFR1 (p55) and TNFR2 (p75). TNFR1 shows a very broad expression pattern, while TNFR2 is preferentially expressed on specific populations of lymphocytes, Tregs, endothelial cells, certain neurons, microglia, cardiomyocytes, and mesenchymal stem cells. In response to receptor activation, very specific biological pathways are activated, although there is some overlap. As a general rule, and not wishing to be bound by theory, TNFR1 signal transduction is associated with the induction of apoptosis (cell death), and TNFR2 signal transduction is associated with cell survival signals (e.g., activation of the NFκB pathway). Administration of TNF is systemically toxic, and this is mainly due to TNFR1 involvement. However, activation of TNFR2 is also associated with a broad range of activities and, like TNFR1, control of TNF targeting and activity is important in the context of the development of TNF-based therapeutics.

[0113] In some embodiments, the modified signaling agent has a reduced affinity and / or activity for TNFR1 and / or TNFR2. In some embodiments, the modified signaling agent has a substantially reduced or eliminated affinity and / or activity for TNFR1 and / or TNFR2. TNFR1 is expressed in most tissues and is associated with cell death signaling, whereas, in contrast, TNFR2 is involved in cell survival signaling. Thus, in embodiments directed to methods for treating cancer, the modified signaling agent has a reduced affinity and / or activity for TNFR1 and / or has a substantially reduced or eliminated affinity and / or activity for TNFR2. In these embodiments, the chimeric protein may be targeted to cells where apoptosis is desired, such as tumor cells or tumor vasculature endothelial cells. In embodiments directed to methods for promoting cell survival, such as in neurogenesis for the treatment of neurodegenerative disorders, the modified signaling agent has a reduced affinity and / or activity for TNFR2 and / or has a substantially reduced or eliminated affinity and / or activity for TNFR1. In other words, the chimeric proteins of the present invention, in some embodiments, contain modified TNF-α agents that allow for the prioritization of either death or survival signals.

[0114] In some embodiments, the chimeric proteins have modified TNF with reduced affinity and / or activity for TNFR1 and / or substantially reduced or eliminated affinity and / or activity for TNFR2. Such chimeras are, in some embodiments, more potent inducers of apoptosis compared to wild-type TNF and / or chimeras with only a mutation(s) that cause reduced affinity and / or activity for TNFR1. Such chimeras, in some embodiments, find use in inducing tumor cell death or tumor vasculature endothelial cell death (e.g., in the treatment of cancer). Also in some embodiments, these chimeras inhibit TNF, e.g., through TNFR2. regThis avoids or reduces cellular activation, thus further supporting TNFR1-mediated anti-tumor activity in vivo.

[0115] In some embodiments, the chimeric protein has a modified TNF with reduced affinity and / or activity for TNFR2 and / or substantially reduced or eliminated affinity and / or activity for TNFR1. Such chimeras are, in some embodiments, more potent activators of cell survival in some cell types, which may be of particular therapeutic interest in a variety of disease settings, including, without limitation, stimulation of neurogenesis. Furthermore, such TNFR2-preferred chimeras are also useful in the treatment of autoimmune diseases (e.g., Crohn's disease, diabetes, MS, colitis, etc., and many others described herein). In some embodiments, the chimeras target autoreactive T cells. In some embodiments, the chimeras target T reg Promotes cell activation and indirect suppression of cytotoxic T cells.

[0116] In some embodiments, the chimeras cause the death of autoreactive T cells, for example, by activation of TNFR2 and / or avoidance of TNFR1 (e.g., modified TNF with reduced affinity and / or activity for TNFR2 and / or substantially reduced or eliminated affinity and / or activity for TNFR1). Without wishing to be bound by theory, these autoreactive T cells have their apoptosis / survival signals altered, for example, by altered NFkB pathway activity / signaling.

[0117] In some embodiments, TNFR2-based chimeras have additional therapeutic applications in diseases including various autoimmune diseases, cardiovascular diseases, demyelinating and neurodegenerative disorders, and infectious diseases, among others.

[0118] In one embodiment, the wild type TNF-α is: TNF-α (SEQ ID NO: 181) VRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL It has the amino acid sequence:

[0119] In such embodiments, the modified TNF-α agent has mutations at one or more of amino acid positions 29, 31, 32, 84, 85, 86, 87, 88, 89, 145, 146, and 147 that result in a modified TNF-α with reduced receptor binding affinity. See, e.g., U.S. Patent No. 7,993,636, the entire contents of which are incorporated herein by reference.

[0120] In some embodiments, the modified human TNF-α portion has mutations at one or more of amino acid positions R32, N34, Q67, H73, L75, T77, S86, Y87, V91, I97, T105, P106, A109, P113, Y115, E127, N137, D143, and A145 (numbering is according to the human TNF sequence, Genbank accession number BAG70306, version BAG70306.1 Gl: 197692685), e.g., as described in WO / 2015 / 007903, the entire contents of which are incorporated herein by reference. In some embodiments, the modified human TNF-α portion has a substitution mutation selected from R32G, N34G, Q67G, H73G, L75G, L75A, L75S, T77A, S86G, Y87Q, Y87L, Y87A, Y87F, V91G, V91A, I97A, I97Q, I97S, T105G, P106G, A109Y, P113G, Y115G, Y115A, E127G, N137G, D143N, A145G and A145T. In one embodiment, the human TNF-α portion has a mutation selected from Y87Q, Y87L, Y87A and Y87F. In another embodiment, the human TNF-α portion has a mutation selected from I97A, I97Q and I97S. In a further embodiment, the human TNF-α portion has a mutation selected from Y115A and Y115G.

[0121] In some embodiments, the modified TNF-α agent has one or more mutations selected from N39Y, S147Y, and Y87H, as described in WO2008 / 124086, the entire contents of which are incorporated herein by reference.

[0122] In some embodiments, the modified human TNF-α portion has mutations that provide receptor selectivity as described in PCT / IB2016 / 001668, the entire contents of which are incorporated herein by reference. In some embodiments, the mutations to TNF are TNF-R1 selective. In some embodiments, the mutations to TNF that are TNF-R1 selective are at one or more of R32, S86, and E146. In some embodiments, the mutations to TNF that are TNF-R1 selective are one or more of R32W, S86T, and E146K. In some embodiments, the mutations to TNF that are TNF-R1 selective are one or more of R32W, R32W / S86T, R32W / E146K, and E146K. In some embodiments, the mutations to TNF are TNF-R2 selective. In some embodiments, the mutations to TNF that are TNF-R2 selective are at one or more of positions A145, E146, and S147. In some embodiments, the mutations to TNF that are TNF-R2 selective are one or more of positions A145T, A145R, E146D, and S147D. In some embodiments, the mutations to TNF that are TNF-R2 selective are one or more of positions A145R, A145T / S147D, and A145T / E146D / S147D.

[0123] In one embodiment, the modified signal transduction agent is TNF-β. TNF-β can form homotrimers or heterotrimers with LT-β (LT-α1β2). In some embodiments, the modified signal transduction agent has substantially reduced or eliminated affinity and / or activity for TNFR1 and / or TNFR2 and / or herpes virus entry mediator (HEVM) and / or LT-βR.

[0124] In one embodiment, the wild type TNF-β is: TNF-β (SEQ ID NO: 182) LPGVGLTPSAAQTARQHPKMHLAHSNLKPAAHLIGDPSKQNSLLWRANTDRAFLQDGFSLSNNSLLVPTSGIYFVYSQVVFSGKAYSPKATSSPLYLAHEVQLFSSQYPFHVPLLSSQKMVYPGLQEPWLHSMYHGAAFQLTQGDQLSTHTDGIPHLVLSPSTVFFGAFAL It has the amino acid sequence:

[0125] In such embodiments, the modified TNF-β agent may include a mutation at one or more amino acids at positions 106-113 that results in a modified TNF-β with reduced receptor binding affinity for TNFR2. In one embodiment, the modified signaling agent has one or more substitution mutations at amino acid positions 106-113. In an exemplary embodiment, the substitution mutations are selected from Q107E, Q107D, S106E, S106D, Q107R, Q107N, Q107E / S106E, Q107E / S106D, Q107D / S106E, and Q107D / S106D. In another embodiment, the modified signaling agent has an insertion of about 1 to about 3 amino acids at positions 106-113.

[0126] In some embodiments, the modifying agent is a TNF family member (e.g., TNF-alpha, TNF-beta), which may be in a single-chain trimer form, as described in WO 2015 / 007903, the entire contents of which are incorporated herein by reference.

[0127] In some embodiments, the modifier is a TNF family member (e.g., TNF-alpha, TNF-beta) that has reduced affinity and / or activity, i.e., antagonistic activity, at TNFR1 (e.g., naturally occurring antagonistic activity, or antagonistic activity that is the result of one or more mutations, see, e.g., WO 2015 / 007520, the entire contents of which are incorporated herein by reference). In these embodiments, the modifier is a TNF family member (e.g., TNF-alpha, TNF-beta) that optionally also has substantially reduced or eliminated affinity and / or activity for TNFR2. In some embodiments, the modifier is a TNF family member (e.g., TNF-alpha, TNF-beta) with reduced affinity and / or activity, i.e., antagonistic activity, at TNFR2 (e.g., naturally occurring antagonistic activity, or antagonistic activity that is the result of one or more mutations, see, e.g., WO 2015 / 007520, the entire contents of which are incorporated herein). In these embodiments, the modifier is a TNF family member (e.g., TNF-alpha, TNF-beta) that also optionally has substantially reduced or eliminated affinity and / or activity for TNFR1. The constructs of these embodiments find use, for example, in methods of attenuating TNF responses in a cell-specific manner. In some embodiments, the antagonistic TNF family member (e.g., TNF-alpha, TNF-beta) is a single-chain trimer type as described in WO2015 / 007903.

[0128] In one embodiment, the modified signal transduction agent is TRAIL. In some embodiments, the modified TRAIL agent has reduced affinity and / or activity for DR4 (TRAIL-RI) and / or DR5 (TRAIL-RII) and / or DcR1 and / or DcR2. In some embodiments, the modified TRAIL agent has substantially reduced or eliminated affinity and / or activity for DR4 (TRAIL-RI) and / or DR5 (TRAIL-RII) and / or DcR1 and / or DcR2.

[0129] In one embodiment, wild type TRAIL is: TRAIL MAMMEVQGGPSLGQTCVLIVIFTVLLQSLCVAVTYVYFTNELKQMQDKYSKSGIACFLKEDDSYWDPNDEESMNSPCWQVKWQLRQLVRKMILRTSEETISTVQEKQQNISPLVRERGPQRVAAHITGTRGRSNTLSSPN SKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG It has the amino acid sequence:

[0130] In such embodiments, the modified TRAIL agent may contain mutations at amino acid positions T127-R132, E144-R149, E155-H161, Y189-Y209, T214-1220, K224-A226, W231, E236-L239, E249-K251, T261-H264 and H270-E271 (numbering based on the human sequence, Genbank accession number NP_003801, version 10 NP_003801.1, Gl:4507593; see above).

[0131] In one embodiment, the modified signaling agent is IL-1. In one embodiment, the modified signaling agent is IL-1α or IL-1β. In one embodiment, the modified signaling agent is IL-1β. In some embodiments, the modified signaling agent has reduced affinity and / or activity for IL-1R1 and / or IL-1RAcP. In some embodiments, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for IL-1R1 and / or IL-1RAcP. In some embodiments, the modified signaling agent has reduced affinity and / or activity for IL-1R2. In some embodiments, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for IL-1R2. For example, in some embodiments, the modified IL-1 agents of the present invention avoid interaction at IL-1R2, thus substantially reducing their function as a decoy and / or sink for therapeutic agents.

[0132] In one embodiment, the wild type IL-1β is: IL-1β (mature type, wild type) APVRSLNCTLRDSQQKSLVMSGPYELKALHLQGQDMEQQVVFSMSFVQGEESNDKIPVALGLKEKNLYLSCVLKDDKPTLQLESVDPKNYPKKKMEKRFVFNKIEINNKLEFESAQFPNWYISTSQAENMPVFLGGTKGGQDITDFTMQFVSS (SEQ ID NO: 183) It has the amino acid sequence:

[0133] IL1 is a pro-inflammatory cytokine and an important regulator of the immune system. It is a potent activator of CD4 T cell responses, increasing the proportion of Th17 cells and the expansion of IFNγ- and IL-4-producing cells. IL-1 also promotes the proliferation of CD8 + A potent regulator of T cells, antigen-specific CD8 +Enhances T cell expansion, differentiation, peripheral migration and memory. IL-1 receptors include IL-1R1 and IL-1R2. Binding to and signaling through IL-1R1 constitutes the mechanism by which IL-1 mediates many of its biological (and pathological) activities. IL1-R2 can function as a decoy receptor, thereby decreasing IL-1 availability for interaction and signaling through IL-1R1.

[0134] In some embodiments, the modified IL-1 has reduced affinity and / or activity (e.g., agonistic activity) for IL-1R1. In some embodiments, the modified IL-1 has substantially reduced or eliminated affinity and / or activity for IL-1R2. In such embodiments, there is restorable IL-1 / IL-1R1 signaling and prevention of therapeutic chimera loss at IL-R2, thus reducing the required IL-1 dose (e.g., compared to wild-type or chimeras with only attenuating mutations for IL-R1). Such constructs find use, for example, in methods of treating cancer, including, for example, stimulating the immune system to generate an anti-cancer response.

[0135] In some embodiments, the modified IL-1 has reduced affinity and / or activity for IL-1R1 (e.g., antagonistic activity, e.g., naturally occurring antagonistic activity, or antagonistic activity that is the result of one or more mutations, see, e.g., WO 2015 / 007520, the entire contents of which are incorporated herein). In some embodiments, the modified IL-1 has substantially reduced or eliminated affinity and / or activity for IL-1R2. In such embodiments, there is no recovery of IL-1 / IL-1R1 signaling and prevention of therapeutic chimera loss at IL-R2, thus reducing the required IL-1 dose (e.g., compared to chimeras carrying only wild-type or attenuating mutations for IL-R1). Such constructs find use in methods of treating, e.g., autoimmune diseases, including, e.g., suppressing the immune system.

[0136] In such embodiments, the modified signal transduction agent has a deletion of amino acids 52-54 that produces a modified human IL-1β with reduced binding affinity for type I IL-1R and reduced biological activity. See, e.g., WO 1994 / 000491, the entire contents of which are incorporated herein by reference. In some embodiments, the modified human IL-1β exhibits reduced binding to IL-1R, as described in WO2015 / 007542 and WO / 2015 / 007536, the entire contents of which are incorporated herein by reference, including A117G / P118G, R120X, L122A, T125G / L126G, R127G, Q130X, Q131G, K132A, S137G / Q138Y, L145G, H146X, L145A / L147A, Q148X, Q148G / Q150G, Q150G / D151A, M152G, F162A, F162A / Q164E, F166A, Q164E / E167K, N169G / D170G, I172A, V174A, K208E, K209X, K209A / K210A, K219X, E221X, E221S / N224A, N224S / K225S, E244K, N245Q (wherein X can be any change in amino acid, e.g., a non-conservative change) (numbering is based on the human IL-1β sequence, Genbank accession number NP_000567, version NP-000567.1, Gl: 10835145). In some embodiments, the modified human IL-1β may have one or more mutations selected from R120A, R120G, Q130A, Q130W, H146A, H146G, H146E, H146N, H146R, Q148E, Q148G, Q148L, K209A, K209D, K219S, K219Q, E221S and E221K. In one embodiment, the modified human IL-1β includes mutations Q131G and Q148G. In one embodiment, the modified human IL-1β includes mutations Q148G and K208E. In one embodiment, the modified human IL-1β includes mutations R120G and Q131G. In one embodiment, the modified human IL-1β includes mutations R120G and H146A.In one embodiment, the modified human IL-1β comprises the mutations R120G and H146N. In one embodiment, the modified human IL-1β comprises the mutations R120G and H146R. In one embodiment, the modified human IL-1β comprises the mutations R120G and H146E. In one embodiment, the modified human IL-1β comprises the mutations R120G and H146A. In one embodiment, the modified human IL-1β comprises the mutations R120G and H146N. In one embodiment, the modified human IL-1β comprises the mutations R120G and H146R. In one embodiment, the modified human IL-1β comprises the mutations R120G and H146E. In one embodiment, the modified human IL-1β comprises the mutations R120G and H146G. In one embodiment, the modified human IL-1β comprises the mutations R120G and K208E. In one embodiment, the modified human IL-1β comprises the mutations R120G, F162A, and Q164E.

[0137] In one embodiment, the modified signaling agent is IL-2. In such embodiments, the modified signaling agent has reduced affinity and / or activity for IL-2Rα and / or IL-2Rβ and / or IL-2Rγ. In some embodiments, the modified signaling agent has reduced affinity and / or activity for IL-2Rβ and / or IL-2Rγ. In some embodiments, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for IL-2Rα. Such embodiments are suitable for treating cancer, e.g., where the modified IL-2 is agonistic at IL-2Rβ and / or IL-2Rγ. For example, the constructs of the invention can be used to bind to CD8 cells bearing IL2 receptors β and γ. + T cells that can favor attenuated activation of T cells (which can provide antitumor effects) and have IL2 receptors α, β, and γ. regIt is also possible to de-prioritize IL-2Rβ and / or IL-2Rγ (which may provide an immunosuppressive tumor-promoting effect). Moreover, in some embodiments, prioritizing IL-2Rβ and / or IL-2Rγ over IL-2Rα avoids IL-2 side effects such as pulmonary edema. IL-2-based chimeras are also useful for treating autoimmune diseases, for example, when the modified IL-2 is antagonistic at IL-2Rβ and / or IL-2Rγ (e.g., naturally occurring antagonistic activity or antagonistic activity that is the result of one or more mutations, see, e.g., WO2015 / 007520, the entire contents of which are incorporated herein). For example, the constructs of the invention may be used to bind CD8 cells bearing IL2 receptors β and γ. + It favors attenuated suppression of T cells (thus weakening the immune response) and is a T reg Alternatively, in some embodiments, the chimeras with IL-2 may not prioritize T reg Activation of CD8 + For example, these constructs find use in the treatment of diseases or disorders that would benefit from immunosuppression, such as autoimmune disorders.

[0138] In some embodiments, the chimeric protein comprises a CD8 + In some embodiments, these constructs have a targeting moiety directed to T cells and a modified IL-2 agent that has reduced affinity and / or activity for IL-2Rβ and / or IL-2Rγ, and / or substantially reduced or eliminated affinity and / or activity for IL-2Rα. + Provides T cell activity, generally T reg In some embodiments, such constructs have enhanced immune stimulatory effects compared to wild-type IL-2 (e.g., without wishing to be bound by theory, by not stimulating Tregs), while eliminating or reducing the systemic toxicity associated with IL-2.

[0139] In one embodiment, the wild type IL-2 is: IL-2 (mature, wild type) APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT (SEQ ID NO: 184) It has the amino acid sequence:

[0140] In such embodiments, the modified IL-2 agent has one or more mutations at amino acids L72 (L72G, L72A, L72S, L72T, L72Q, L72E, L72N, L72D, L72R, or L72K), F42 (F42A, F42G, F42S, F42T, F42Q, F42E, F42N, F42D, F42R, or F42K) and Y45 (Y45A, Y45G, Y45S, Y45T, Y45Q, Y45E, Y45N, Y45D, Y45R, or Y45K). Without wishing to be bound by theory, it is believed that these modified IL-2 agents have reduced affinity for the high affinity IL-2 receptor and retain affinity for the medium affinity IL-2 receptor when compared to wild-type IL-2 (see, e.g., U.S. Patent Publication No. 2012 / 0244112, the entire contents of which are incorporated herein by reference).

[0141] In one embodiment, the modified signaling agent is IL-3. In some embodiments, the modified signaling agent has reduced affinity and / or activity for IL-3 receptor, which is a heterodimer with a unique alpha chain paired with a common beta (beta c or CD131) subunit. In some embodiments, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for IL-3 receptor, which is a heterodimer with a unique alpha chain paired with a common beta (beta c or CD131) subunit.

[0142] In one embodiment, the modified signaling agent is IL-4. In such embodiments, the modified signaling agent has reduced affinity and / or activity for type 1 and / or type 2 IL-4 receptors. In such embodiments, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for type 1 and / or type 2 IL-4 receptors. Type 1 IL-4 receptor is composed of a common gamma chain and an IL-4Rα subunit, which specifically binds IL-4. Type 2 IL-4 receptor comprises an IL-4Rα subunit bound to a different subunit known as IL-13Rα1. In some embodiments, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for type 2 IL-4 receptors.

[0143] In one embodiment, the wild type IL-4 is: IL-4 (mature type, wild type) HKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAASKNTTEKETFCRAATVLRQFYSHHEKDTRCLGATAQQFHRHKQLIRFLKRLDRNLWGLAGLNSCPVKEANQSTLENFLERLKTIMREKYSKCSS (SEQ ID NO: 185) It has the amino acid sequence:

[0144] In such embodiments, the modified IL-4 agents have one or more mutations at amino acids R121 (R121A, R121D, R121E, R121F, R121H, R121I, R121K, R121N, R121P, R121T, R121W), E122 (E122F), Y124 (Y124A, Y124Q, Y124R, Y124S, Y124T) and S125 (S125A). Without wishing to be bound by theory, these modified IL-4 agents maintain activity mediated by type 1 receptors but significantly reduce biological activity mediated by other receptors. See, e.g., U.S. Patent No. 6,433,157, the entire contents of which are incorporated herein by reference.

[0145] In one embodiment, the modified signaling agent is IL-6. IL-6 signals through a cell surface type I cytokine receptor complex that includes the ligand-binding IL-6R chain (CD126) and the signaling component gp130. IL-6 can also bind to the soluble form of IL-6R (sIL-6R), which is the extracellular portion of IL-6R. The sIL-6R / IL-6 complex may be involved in neurite outgrowth and neuronal survival, and thus may be important in neural regeneration through remyelination. Thus, in some embodiments, the modified signaling agent has a reduced affinity and / or activity for IL-6R / gp130 and / or sIL-6R. In some embodiments, the modified signaling agent has a substantially reduced or eliminated affinity and / or activity for IL-6R / gp130 and / or sIL-6R.

[0146] In one embodiment, the wild type IL-6 is: IL-6 (mature type, wild type) APVPPGEDSKDVAAPHRQPLTSSERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQKKAKNLDAITTPDPTTNASLTTKLQAQNQWLQDMTTHLILRSFKEFLQSSLRALRQM (SEQ ID NO: 186) It has the amino acid sequence:

[0147] In such embodiments, the modified signal transduction agent has one or more mutations at amino acid 58, 160, 163, 171 or 177. Without wishing to be bound by theory, these modified IL-6 agents show reduced binding affinity to IL-6R alpha and reduced biological activity. See, for example, WO97 / 10338, the entire contents of which are incorporated herein by reference.

[0148] In one embodiment, the modified signaling agent is IL-10. In such embodiments, the modified signaling agent has reduced affinity and / or activity for IL-10 receptor-1 and IL-10 receptor-2. In some embodiments, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for IL-10 receptor-1 and IL-10 receptor-2.

[0149] In one embodiment, the modified signaling agent is IL-11. In such an embodiment, the modified signaling agent has reduced affinity and / or activity for IL-11Rα and / or IL-11Rβ and / or gp130. In such an embodiment, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for IL-11Rα and / or IL-11Rβ and / or gp130.

[0150] In one embodiment, the modified signaling agent is IL-12. In such embodiments, the modified signaling agent has reduced affinity and / or activity for IL-12Rβ1 and / or IL-12Rβ2. In such embodiments, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for IL-12Rβ1 and / or IL-12Rβ2.

[0151] In one embodiment, the modified signaling agent is IL-13. In such embodiments, the modified signaling agent has reduced affinity and / or activity for IL-4 receptor (IL-4Rα) and IL-13Rα1. In some embodiments, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for IL-4 receptor (IL-4Rα) and IL-13Rα1.

[0152] In one embodiment, the wild type IL-13 is: IL-13 (mature type, wild type) SPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN (SEQ ID NO: 187) It has the amino acid sequence:

[0153] In such embodiments, the modified IL-13 agents have one or more mutations at amino acids 13, 16, 17, 66, 69, 99, 102, 104, 105, 106, 107, 108, 109, 112, 113 and 114. Without wishing to be bound by theory, these modified IL-13 agents exhibit reduced biological activity. See, e.g., WO 2002 / 018422, the entire contents of which are incorporated herein by reference.

[0154] In one embodiment, the modified signaling agent is IL-18. In some embodiments, the modified signaling agent has reduced affinity and / or activity for IL-18Rα and / or IL-18Rβ. In some embodiments, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for IL-18Rα and / or IL-18Rβ. In some embodiments, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for type II IL-18Rα, an isoform of IL-18Rα that lacks the TIR domain required for signal transduction.

[0155] In one embodiment, the wild type IL-18 is: IL-18 (wild type) MAAEPVEDNCINFVAMKFIDNTLYFIAEDDENLESDYFGKLESKLSVIRNLNDQVLFIDQGNRPLFEDMTDSDCRDNAPRTIFIISMYKDSQPRGMAVTISVKCEKISTLSCENKIISFKEMNPPDNIKDTKSDIIFFQRSVPGHDNKMQFESSSYEGYFLACEKERDLFKLILKKEDELGDRSIMFTVQNEDL (SEQ ID NO: 188) It has the amino acid sequence:

[0156] In such embodiments, the modified IL-18 agent may include one or more mutations at amino acids or amino acid regions selected from Y37-K44, R49-Q54, D59-R63, E67-C74, R80, M87-A97, N127-K129, Q139-M149, K165-K171, R183 and Q190-N191, as described in WO / 2015 / 007542, the entire contents of which are incorporated herein by reference (numbering is based on human IL-18 SEQ ID NO:, Genbank Accession No. AAV38697, version AAV38697.1, Gl: 54696650).

[0157] In one embodiment, the modified signaling agent is IL-33. In such embodiments, the modified signaling agent has reduced affinity and / or activity for the ST-2 receptor and IL-1RAcP. In some embodiments, the modified signaling agent has substantially reduced or eliminated affinity and / or activity for the ST-2 receptor and IL-1RAcP.

[0158] In one embodiment, the wild type IL-33 is: IL-33 (wild type) MKPKMKYSTNKISTAKWKNTASKALCFKLGKSQQKAKEVCPMYFMKLRSGLMIKKEACYFRRETTKRPSLKTGRKHKRHLVLAACQQQSTVECFAFGISGVQKYTRALHDSSITGISPITEYLASLSTYNDQSITFALEDESYEIYVEDLKKDEKKDKVLLSYYESQHPSNESGDGVDGKMLMVTLSPTKDFWLHANNKEHSVELHKCEKPLPDQAFFVLHNMHSNCVSFECKTDPGVFIGVKDNHLALIKVDSSENLCTENILFKLSET (SEQ ID NO: 189) It has the amino acid sequence:

[0159] In such embodiments, the modified IL-33 agent may include one or more mutations in amino acids or amino acid regions selected from I113-Y122, S127-E139, E144-D157, Y163-M183, E200, Q215, L220-C227 and T260-E269, as described in WO / 2015 / 007542, the entire contents of which are incorporated herein by reference (numbering is based on the human sequence, Genbank Accession No. NP_254274, version NP_254274.1, Gl:15559209).

[0160] Linker In some embodiments, the chimeric proteins of the invention optionally include one or more linkers. In some embodiments, the chimeric proteins of the invention include a linker that connects the targeting moiety and the signaling agent. In some embodiments, the chimeric proteins of the invention include a linker within the signaling agent (e.g., in the case of single-chain TNF, it can include two linkers to generate a trimer).

[0161] In some embodiments, vectors are provided that encode the chimeric proteins of the invention linked as a single nucleotide sequence to any of the linkers described herein and can be used to prepare such chimeric proteins.

[0162] In some embodiments, the length of the linker allows the targeting moiety and the signal transduction agent to be efficiently bound to its receptor.For example, in some embodiments, the length of the linker allows one of the targeting moieties and the signal transduction agent to be efficiently bound to the receptor on the same cell, and the other targeting moiety to be efficiently bound to another cell.Exemplary pairs of cells are provided elsewhere herein.

[0163] In some embodiments, the length of the linker is at least equal to the minimum distance between one of the targeting moieties and the binding site of the signaling agent to the receptor on the same cell.In some embodiments, the length of the linker is at least 2 times, or 3 times, or 4 times, or 5 times, or 10 times, or 20 times, or 25 times, or 50 times, or 100 times, or more than the minimum distance between one of the targeting moieties and the binding site of the signaling agent to the receptor on the same cell.

[0164] As described herein, the length of the linker allows for efficient binding of one of the targeting moieties and the signaling agent to a receptor on the same cell, and the binding is sequential, e.g., targeting moiety / receptor binding precedes signaling agent / receptor binding.

[0165] In some embodiments, there are two linkers in a single chimera, each linking a signaling agent to a targeting moiety. In various embodiments, the linkers have a length that allows for the formation of a site with disease cells and effector cells without steric hindrance that would prevent modulation of either cell.

[0166] The present invention contemplates the use of various linker sequences. In various embodiments, the linker may be derived from naturally occurring multidomain proteins or may be an empirical linker, for example, as described in Chichili et al. (2013), Protein Sci. 22(2):153-167, Chen et al. (2013), Adv Drug Deliv Rev. 65(10):1357-1369, the entire contents of which are incorporated herein by reference. In some embodiments, the linker may be designed using a linker design database or computer program, such as those described in Chen et al. (2013), Adv Drug Deliv Rev. 65(10):1357-1369 and Crasto et al. (2000), Protein Eng. 13(5):309-312, the entire contents of which are incorporated herein by reference. In various embodiments, the linker may be functional. For example, without limitation, a linker may function to improve folding and / or stability, improve expression, improve pharmacokinetics, and / or improve the biological activity of a chimeric protein of the present invention.

[0167] In some embodiments, the linker is a polypeptide. In some embodiments, the linker is less than about 100 amino acids in length. For example, the linker can be less than about 100, about 95, about 90, about 85, about 80, about 75, about 70, about 65, about 60, about 55, about 50, about 45, about 40, about 35, about 30, about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, or about 2 amino acids in length. In some embodiments, the linker is a polypeptide. In some embodiments, the linker is more than about 100 amino acids in length. For example, the linker may be greater than about 100, about 95, about 90, about 85, about 80, about 75, about 70, about 65, about 60, about 55, about 50, about 45, about 40, about 35, about 30, about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, or about 2 amino acids in length. In some embodiments, the linker is flexible. In other embodiments, the linker is rigid.

[0168] In some embodiments, some linkers connect two targeting moieties to each other, and the linkers have a short length, and some linkers connect targeting moieties and signaling agents, and the linkers are longer than the linkers that connect two targeting moieties.For example, the difference in amino acid length between the linkers that connect two targeting moieties and the linkers that connect targeting moieties and signaling agents can be about 100, about 95, about 90, about 85, about 80, about 75, about 70, about 65, about 60, about 55, about 50, about 45, about 40, about 35, about 30, about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3 or about 2 amino acids.

[0169] In various embodiments, the linker is substantially composed of glycine and serine residues (e.g., about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 97% glycine and serine). For example, in some embodiments, the linker is (Gly4Ser) n where n is from about 1 to about 8, e.g., 1, 2, 3, 4, 5, 6, 7, or 8. In one embodiment, the linker sequence is GGSGGSGGGGSGGGGS (SEQ ID NO: 190). Further exemplary linkers include, but are not limited to, the sequences LE, GGGGS (SEQ ID NO: 191), (GGGGS) n (n = 1 to 4) (SEQ ID NO: 192) 、 (Gly)8 (SEQ ID NO: 193), (Gly)6 (SEQ ID NO: 194), (EAAAK) n (n = 1 to 3) (SEQ ID NO: 195), A (EAAAK) n A (n = 2 to 5) (SEQ ID NO: 196), AEAAAKEAAAKA (SEQ ID NO: 197), A(EAAAK)4ALEA(EAAAK)4A (SEQ ID NO: 198), PAPAP (SEQ ID NO: 199), KESGSVSSEQLAQFRSLD (SEQ ID NO: 200), EGKSSGSGSESKST (SEQ ID NO: 201), GSAGSAAGSGEF (SEQ ID NO: 202), and (XP) n wherein X represents any amino acid, such as Ala, Lys, or Glu. In various embodiments, the linker is GGS.

[0170] In some embodiments, the linker is an antibody hinge region (e.g., of the IgG, IgA, IgD, and IgE subclasses, e.g., IgG1, IgG2, IgG3, and IgG4, as well as IgA1 and IgA2). In various embodiments, the linker is an antibody hinge region (e.g., of the IgG, IgA, IgD, and IgE subclasses, e.g., IgG1, IgG2, IgG3, and IgG4, as well as IgA1 and IgA2). The hinge region found in IgG, IgA, IgD, and IgE class antibodies acts as a flexible spacer, allowing the Fab portion to move freely in space. In contrast to constant regions, hinge domains are structurally diverse, varying in both sequence and length among immunoglobulin classes and subclasses. For example, the length and flexibility of the hinge region varies among IgG subclasses. The hinge region of IgG1 contains amino acids 216-231 and is so flexible that the Fab fragment can rotate around an axis of symmetry and move within a sphere centered on the first of the two inter-heavy chain disulfide bridges. IgG2 has a shorter hinge than IgG1, with 12 amino acid residues and four disulfide bridges. The hinge region of IgG2 lacks glycine residues, is relatively short, and contains a rigid polyproline double helix that is stabilized by an additional inter-heavy chain disulfide bridge. These properties limit the flexibility of the IgG2 molecule. IgG3 differs from the other subclasses by its unique extended hinge region (about four times longer than the IgG1 hinge), which contains 62 amino acids (including 21 prolines and 11 cysteines) and forms a non-flexible polyproline double helix. In IgG3, the Fab fragment is relatively far from the Fc fragment, giving the molecule greater flexibility. The extended hinge in IgG3 is also responsible for its higher molecular weight compared to other subclasses. The hinge region of IgG4 is shorter than that of IgG1, and its flexibility is intermediate between that of IgG1 and IgG2. The flexibility of the hinge region is reported to decrease in the order IgG3>IgG1>IgG4>IgG2.

[0171] According to crystallographic studies, immunoglobulin hinge regions can be further subdivided functionally into three regions: the upper hinge region, the core region, and the lower hinge region. See Shin et al., 1992 Immunological Reviews 130:87. The upper hinge region is H1 The upper hinge region contains amino acids from the carboxyl end of the hinge to the first residue in the hinge that restricts movement, typically the first cysteine ​​residue that forms the interchain disulfide bond between the two heavy chains. The length of the upper hinge region correlates with the segmental flexibility of the antibody. The core hinge region contains the interchain disulfide bridges, and the lower hinge region contains the C H2 The amino termini of the domains are linked together, H2 Id. The core hinge region of wild-type human IgG1 contains the sequence Cys-Pro-Pro-Cys, which when dimerized by disulfide bond formation results in a cyclic octapeptide that is believed to act as a pivot, thus providing flexibility. In various embodiments, the linkers of the invention comprise one, two, or three of the upper hinge region, core region, and lower hinge region of an antibody (e.g., of IgG, IgA, IgD, and IgE, including subclasses such as IgG1, IgG2, IgG3, and IgG4, as well as IgA1 and IgA2). The hinge region may also contain one or more glycosylation sites, which include several structurally distinct types for carbohydrate attachment. For example, IgA1 contains five glycosylation sites within a 17 amino acid segment of the hinge region, conferring resistance of the hinge region polypeptide to intestinal proteases, a property believed to be favorable for secretory immunoglobulins. In various embodiments, the linker of the invention comprises one or more glycosylation sites. In various embodiments, the linker is the hinge-CH2-CH3 domain of a human IgG4 antibody.

[0172] If desired, the chimeric protein of the invention may be H 2 and C HIt may be linked to an antibody Fc region, including one or both of the three domains, and optionally a hinge region. For example, a vector encoding the chimeric protein of the present invention linked as a single nucleotide sequence to an Fc region may be used to prepare such a polypeptide.

[0173] In some embodiments, the linker is a synthetic linker, such as PEG.

[0174] In various embodiments, the linker may be functional. For example, without limitation, the linker may function to improve folding and / or stability, improve expression, improve pharmacokinetics, and / or improve the biological activity of the chimeric protein of the present invention. In another example, the linker may function to target the chimeric protein to a specific cell type or location.

[0175] In various embodiments, the chimeric protein may be conjugated and / or fused with another agent to extend half-life or improve pharmacokinetic and pharmacodynamic properties. In some embodiments, the chimeric protein may be fused or conjugated with one or more of PEG, XTEN (e.g., rPEG), polysialic acid (POLYXEN), albumin (e.g., human serum albumin or HAS), elastin-like protein (ELP), PAS, HAP, GLK, CTP, transferrin, etc. In some embodiments, the chimeric protein may be fused or conjugated to an antibody or an antibody fragment, such as an Fc fragment. For example, the chimeric protein may be fused to either the N-terminus or C-terminus of the Fc domain of human immunoglobulin (Ig) G. In various embodiments, each of the individual chimeric proteins is fused to one or more of the agents described in BioDrugs (2015) 29:215-239, the entire contents of which are incorporated herein by reference.

[0176] Production of chimeric proteins The method for producing the chimeric protein of the present invention is described herein.For example, the DNA sequence encoding the chimeric protein of the present invention (e.g., the DNA sequence encoding the modified signal transduction agent and the targeting moiety and the linker) can be chemically synthesized using methods known in the art.The synthetic DNA sequence can be linked to other suitable nucleotide sequences, including, for example, expression control sequences, to produce a gene expression construct encoding the desired chimeric protein.Thus, in various embodiments, the present invention provides an isolated nucleic acid comprising a nucleotide sequence encoding the chimeric protein of the present invention.

[0177] The nucleic acid encoding the chimeric protein of the present invention can be incorporated (linked) into an expression vector, and the vector can be introduced into a host cell through transfection, transformation, or transduction techniques. For example, the nucleic acid encoding the chimeric protein of the present invention can be introduced into a host cell by retroviral transduction. Exemplary host cells are Escherichia coli (E. coli) cells, Chinese hamster ovary (CHO) cells, human embryonic kidney 293 (HEK293) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and myeloma cells. The transformed host cells can be grown under conditions that allow the host cells to express the gene encoding the chimeric protein of the present invention. Thus, in various embodiments, the present invention provides an expression vector comprising a nucleic acid encoding the chimeric protein of the present invention. In various embodiments, the present invention further provides a host cell comprising such an expression vector.

[0178] Specific expression and purification conditions will vary depending on the expression system used.For example, if a gene is expressed in E. coli, it is first cloned into an expression vector by placing the gene to be manipulated downstream from a suitable bacterial promoter, such as Trp or Tac, and a prokaryotic signal sequence.In another example, if a gene to be manipulated is expressed in a eukaryotic host cell, such as a CHO cell, it is first inserted into an expression vector that contains, for example, a suitable eukaryotic promoter, secretion signal, enhancer, and various introns.The gene construct can be introduced into the host cell by using transfection, transformation, or transduction techniques.

[0179] The chimeric proteins of the invention can be produced by growing host cells transfected with an expression vector encoding the chimeric protein under conditions that allow expression of the protein. Following expression, the protein can be harvested and purified using techniques well known in the art, for example, affinity tags such as glutathione-S-transferase (GST) and histidine tags, or by chromatography.

[0180] Thus, in various embodiments, the invention provides a nucleic acid encoding a chimeric protein of the invention.In various embodiments, the invention provides a host cell comprising a nucleic acid encoding a chimeric protein of the invention.

[0181] Pharmaceutically acceptable salts and excipients The chimeric proteins described herein have sufficiently basic functional groups capable of reacting with inorganic or organic acids, or carboxyl groups capable of reacting with inorganic or organic bases, to form pharma- ceutically acceptable salts. Pharmaceutically acceptable acid addition salts are formed from pharma- ceutically acceptable acids, as is well known in the art. Such salts include, for example, the pharma- ceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2-19 (1977) and The Handbook of Pharmaceutical Salts; Properties, Selection, and Use. PH Stahl and CG Wermuth (eds.), Verlag, Zurich (Switzerland) 2002, which are incorporated herein in their entirety.

[0182] Pharmaceutically acceptable salts include, by way of non-limiting example, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, perphosphate, isonicotinate, lactate, salicylate, percitrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, pamoate, phenylacetate, trifluoroacetate, acrylate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, benzoic acid salts, benzoates ... These include benzoate, naphthalene-2-benzoate, isobutyrate, phenylbutyrate, alpha-hydroxybutyrate, butyne-1,4-dicarboxylate, hexyne-1,4-dicarboxylate, caprate, caprylate, cinnamate, glycolate, heptanoate, hippurate, malate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, phthalate, teraphthalate, propiolate, propionate, phenylpropionate, sebacate, suberate, p-bromobenzenesulfonate, chlorobenzenesulfonate, ethylsulfonate, 2-hydroxyethylsulfonate, methylsulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, naphthalene-1,5-sulfonate, xylenesulfonate, and tartrate.

[0183] The term "pharmaceutically acceptable salt" also refers to a salt of a composition of the present invention that has an acidic functional group, such as a carboxylic acid functional group, and a base. Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metals such as calcium and magnesium; hydroxides of other metals such as aluminum and zinc; ammonia, and organic amines such as unsubstituted or hydroxy-substituted mono-, di-, or trialkylamines, dicyclohexylamine; tributylamine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-lower alkylamines), such as mono-, bis-, or tris-(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine, or tris-(hydroxymethyl)methylamine, N,N-di-lower alkyl-N-(hydroxyl-lower alkyl)-amines, such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine; N-methyl-D-glucamine; and amino acids such as arginine, lysine, and the like.

[0184] In some embodiments, the compositions described herein are in the form of a pharma- ceutically acceptable salt.

[0185] Pharmaceutical Compositions and Formulations In various embodiments, the present invention relates to a pharmaceutical composition comprising the chimeric protein described herein and a pharma- ceutically acceptable carrier or excipient. Any of the pharmaceutical compositions described herein can be administered to a subject as a component of a composition comprising a pharma- ceutically acceptable carrier or vehicle. Such compositions may optionally include a suitable amount of a pharma- ceutically acceptable excipient to provide a suitable form for administration.

[0186] In various embodiments, pharmaceutical excipients may be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Pharmaceutical excipients may be, for example, saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary agents, stabilizers, thickening agents, lubricants, and coloring agents can be used. In one embodiment, the pharmaceutically acceptable excipients are sterile when administered to a subject. When any of the agents described herein are administered intravenously, water is a useful excipient. Saline solutions and aqueous dextrose and glycerol solutions can also be used as liquid excipients, particularly for injectable solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, etc. Any of the agents described herein may also contain minor amounts of wetting or emulsifying agents, or pH buffering agents, if desired. Other examples of suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (ed. Alfonso R. Gennaro, 19th ed. 1995), which is incorporated herein by reference.

[0187] The present invention includes the described pharmaceutical compositions (and / or additional therapeutic agents) in a variety of formulations. Any of the pharmaceutical compositions of the present invention (and / or additional therapeutic agents) described herein may take the form of a solution, suspension, emulsion, droplets, tablets, pills, pellets, capsules, capsules containing liquid, gelatin capsules, powders, sustained release formulations, suppositories, emulsions, aerosols, sprays, suspensions, lyophilized powders, frozen suspensions, dry powders, or any other form suitable for use. In one embodiment, the composition is in the form of a capsule. In another embodiment, the composition is in the form of a tablet. In yet another embodiment, the pharmaceutical composition is formulated in the form of a softgel capsule. In a further embodiment, the pharmaceutical composition is formulated in the form of a gelatin capsule. In yet another embodiment, the pharmaceutical composition is formulated as a liquid.

[0188] If necessary, the pharmaceutical composition of the present invention (and / or additional agent) may also include a solubilizing agent.The agent can also be delivered in a suitable vehicle or delivery device known in the art.The combination therapy outlined herein can also be co-delivered in a single delivery vehicle or delivery device.

[0189] The formulations containing the pharmaceutical composition (and / or additional agent) of the present invention may be conveniently presented in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical industry. Such methods generally include the step of bringing the therapeutic agent into association with a carrier which constitutes one or more accessory ingredients. Typically, the formulations are prepared by uniformly and intimately bringing the therapeutic agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into a dosage form of the desired formulation (e.g., wet or dry granulation, powder blending, etc., followed by tableting, using conventional methods known in the art).

[0190] In various embodiments, any pharmaceutical composition described herein (and / or additional agents) are formulated by routine methods into compositions adapted for the modes of administration described herein.

[0191] Routes of administration include, for example: oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectal, by inhalation or topical routes. Administration may be local or systemic. In some embodiments, administration is accomplished orally. In other embodiments, administration is by parenteral injection. The mode of administration may be left to the discretion of the practitioner and will depend, in part, on the site of the medical condition. In most instances, administration will result in the release of any agent described herein into the bloodstream.

[0192] In one embodiment, the chimeric protein described herein is formulated by routine methods as a composition adapted for oral administration. The composition for oral delivery may be in the form of, for example, a tablet, lozenge, aqueous or oily suspension, granule, powder, emulsion, capsule, syrup, or elixir. The oral administration composition may contain one or more agents, such as sweeteners, such as fructose, aspartame, or saccharin; flavoring agents, such as peppermint, wintergreen, or cherry oil; coloring agents; and preservatives, to provide a pharma-ceutically palatable preparation. In addition, when in tablet or pill form, the composition may be coated to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over an extended period of time. A selectively permeable membrane surrounding any of the osmotically active driving chimeric proteins described herein is also suitable for oral administration compositions. In these latter platforms, liquid from the environment surrounding the capsule is absorbed by the driving compound, which expands and releases the agent or agent composition through an opening. These delivery platforms can provide an essentially zero-order delivery profile, as opposed to the spiked profiles of immediate release formulations.Time-delay materials, such as glycerol monostearate or glycerol stearate, can also be useful.Oral compositions can contain standard excipients, such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate.In one embodiment, the excipients are of pharmaceutical grade.Suspensions can contain, in addition to active compound, suspending agents, such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, tragacanth, and the like, and mixtures thereof.

[0193] Dosage forms suitable for parenteral administration (e.g., intravenous, intramuscular, intraperitoneal, subcutaneous and intraarterial injection and infusion) include, for example, solutions, suspensions, dispersions, emulsions, etc. They can also be prepared in the form of sterile solid compositions (e.g., lyophilized compositions), which can be dissolved or suspended in a sterile injectable medium immediately before use. They may, for example, contain suspending or dispersing agents known in the art. Formulation components suitable for parenteral administration include sterile diluents, such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as EDTA; buffers, such as acetates, citrates or phosphates; and osmolality regulators, such as sodium chloride or dextrose.

[0194] For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). The carrier must be stable under the conditions of manufacture and storage and must be preserved against microorganisms. The carrier can be, for example, a solvent or dispersion medium containing water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof.

[0195] The compositions provided herein, alone or in combination with other suitable components, may be made into aerosol formulations (i.e., "nebulized") to be administered via inhalation. The aerosol formulations can also be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

[0196] Any of the pharmaceutical compositions of the present invention (and / or additional agents) described herein can be administered by sustained release or sustained release means or by delivery devices known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; and 5,733,556, each of which is incorporated herein in its entirety. Such dosage forms are useful for providing slow or sustained release of one or more active ingredients, for example, by using hydropropyl cellulose, hydropropyl methyl cellulose, polyvinylpyrrolidone, other polymer matrices, gels, permeable membranes, osmotic systems, multi-layer coatings, microparticles, liposomes, microspheres, or combinations thereof, to provide desired release profiles at various ratios.Suitable slow or sustained release formulations known to those skilled in the art, including those described herein, can be easily selected for use with the active ingredients of the agent described herein.The present invention thus provides single unit dosage forms suitable for oral administration, such as, but not limited to, tablets, capsules, gelcaps, and caplets adapted for slow or sustained release.

[0197] Controlled or sustained release of an active ingredient may be stimulated by a variety of conditions including, but not limited to, pH change, temperature change, stimulation with light of appropriate wavelengths, enzyme concentration or availability, water concentration or availability, or other physiological conditions or compounds.

[0198] In another embodiment, a sustained release system can be placed in the vicinity of the target area to be treated, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other sustained release systems discussed in the review by Langer, 1990, Science 249:1527-1533 can be used.

[0199] The pharmaceutical formulation is preferably sterile. Sterilization can be achieved, for example, by filtration through a sterile filtration membrane. If the composition is lyophilized, filter sterilization can be performed before or after lyophilization and reconstitution.

[0200] Administration and Dosage It will be appreciated that the actual dose of chimeric protein to be administered according to the present invention will vary depending on the particular dosage form and mode of administration. Many factors that may modify the action of chimeric protein (e.g., body weight, sex, diet, administration time, administration route, excretion rate, condition of the subject, drug combinations, genetic predisposition and reaction sensitivity) may be taken into consideration by those skilled in the art. Administration may be performed continuously or in one or more separate doses within the maximum tolerated dose. Optimal dosage rates for a given set of conditions can be ascertained by those skilled in the art using routine dosage form administration tests.

[0201] In some embodiments, a suitable dosage of the chimeric protein is in the range of about 0.01 mg / kg to about 10 g / kg of the subject's body weight, about 0.01 mg / kg to about 1 g / kg of the subject's body weight, about 0.01 mg / kg to about 100 mg / kg of the subject's body weight, about 0.01 mg / kg to about 10 mg / kg of the subject's body weight, e.g., about 0.01 mg / kg, about 0.02 mg / kg, about 0.03 mg / kg, about 0.04 mg / kg, about 0.05 mg / kg, about 0.06 mg / kg, about 0.07 mg / kg, about 0.08 mg / kg, about 0.09 mg / kg, about 0.1 mg / kg, about 0.2 mg / kg, about 0.3 mg / kg, about 0.4 mg / kg, about 0.6 mg / kg, about 0.8 mg / kg, about 0.9 mg / kg, about 0.1 mg / kg, about 0.2 mg / kg, about 0.3 mg / kg, about 0.4 ... g / kg, about 0.5 mg / kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, about 0.9 mg / kg, about 1 mg / kg, about 1.1 mg / kg, about 1.2 mg / kg, about 1.3 mg / kg, about 1.4 mg / kg, about 1.5 mg / kg, about 1.6 mg / kg, about 1.7 mg / kg, about 1.8 mg / kg, about 1.9 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 100 mg / kg, about 1 g / kg, about 10 g / kg, including all values ​​and ranges therebetween.

[0202] Individual doses of the chimeric protein are, for example, about 0.01 mg to about 100 g, about 0.01 mg to about 75 g, about 0.01 mg to about 50 g, about 0.01 mg to about 25 g, about 0.01 mg to about 10 g, about 0.01 mg to about 7.5 g, about 0.01 mg to about 5 g, about 0.01 mg to about 2.5 g, about 0.01 mg to about 1 g, about 0.01 mg to about 100 mg, about 0.1 mg to about 100 mg, about 0.1 mg to about 9 ... The active ingredient may be administered in a unit dosage form (e.g., tablet or capsule) containing about 0.1 mg to about 80 mg, about 0.1 mg to about 70 mg, about 0.1 mg to about 60 mg, about 0.1 mg to about 50 mg, about 0.1 mg to about 40 mg of active ingredient, about 0.1 mg to about 30 mg, about 0.1 mg to about 20 mg, about 0.1 mg to about 10 mg, about 0.1 mg to about 5 mg, about 0.1 mg to about 3 mg, about 0.1 mg to about 1 mg, or about 5 mg to about 80 mg per unit dosage. For example, unit dosage forms may include about 0.01 mg, about 0.02 mg, about 0.03 mg, about 0.04 mg, about 0.05 mg, about 0.06 mg, about 0.07 mg, about 0.08 mg, about 0.09 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about The amount may be about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 200 mg, about 500 mg, about 1 g, about 2.5 g, about 5 g, about 10 g, about 25 g, about 50 g, about 75 g, about 100 g, including all values ​​and ranges therebetween.

[0203] In one embodiment, the chimeric protein is administered at a dose of about 0.01 mg to about 100 g daily, about 0.01 mg to about 75 g daily, about 0.01 mg to about 50 g daily, about 0.01 mg to about 25 g daily, about 0.01 mg to about 10 g daily, about 0.01 mg to about 7.5 g daily, about 0.01 mg to about 5 g daily, about 0.01 mg to about 2.5 g daily, about 0.01 mg to about 1 g daily, about 0.01 mg to about 100 mg daily, about 0.1 mg to about 100 mg daily, about 0.1 mg to about 95 mg daily, about 0.1 mg to about 90 mg daily, about 0.1 mg to about 85 mg daily, about 0.1 mg to about 80 mg daily, about 0.1 mg to about 75 mg daily g daily, about 0.1 mg to about 70 mg daily, about 0.1 mg to about 65 mg daily, about 0.1 mg to about 60 mg daily, about 0.1 mg to about 55 mg daily, about 0.1 mg to about 50 mg daily, about 0.1 mg to about 45 mg daily, about 0.1 mg to about 40 mg daily, about 0.1 mg to about 35 mg daily, about 0.1 mg to about 30 mg daily, about 0.1 mg to about 25 mg daily, about 0.1 mg to about 20 mg daily, about 0.1 mg to about 15 mg daily, about 0.1 mg to about 10 mg daily, about 0.1 mg to about 5 mg daily, about 0.1 mg to about 3 mg daily, about 0.1 mg to about 1 mg daily, or about 5 mg to about 80 mg daily. In various embodiments, the chimeric protein is present at about 0.01 mg, about 0.02 mg, about 0.03 mg, about 0.04 mg, about 0.05 mg, about 0.06 mg, about 0.07 mg, about 0.08 mg, about 0.09 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about and / or administered in a daily dose of about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 200 mg, about 500 mg, about 1 g, about 2.5 g, about 5 g, about 7.5 g, about 10 g, about 25 g, about 50 g, about 75 g, about 100 g, including all values ​​and ranges therebetween.

[0204] According to certain embodiments of the invention, pharmaceutical compositions comprising the chimeric protein may be administered, for example, more than once a day (e.g., about twice, about three times, about four times, about five times, about six times, about seven times, about eight times, about nine times, or about ten times a day), about once per day, about every other day, about every third day, about once per week, about once every two weeks, about once per month, about once every two months, about once every three months, about once every six months, or about once per year.

[0205] Combination Therapies and Additional Therapeutic Agents In various embodiments, the pharmaceutical compositions of the present invention are co-administered in combination with an additional therapeutic agent(s). The co-administration may be simultaneous or sequential.

[0206] In one embodiment, the additional therapeutic agent and the chimeric protein of the present invention are administered to the subject simultaneously. As used herein, the term "simultaneously" means that the additional therapeutic agent and the chimeric protein are administered at a time interval not exceeding about 60 minutes, for example not exceeding about 30 minutes, not exceeding about 20 minutes, not exceeding about 10 minutes, not exceeding about 5 minutes, or not exceeding about 1 minute. The administration of the additional therapeutic agent and the chimeric protein can also be by simultaneous administration of a single formulation (e.g., a formulation comprising the additional therapeutic agent and the chimeric protein) or separate formulations (e.g., a first formulation comprising the additional therapeutic agent and a second formulation comprising the chimeric protein).

[0207] Co-administration does not require that the therapeutic agents be administered at the same time, provided that the timing of their administration is such that the pharmacological activities of the additional therapeutic agent and the chimeric protein overlap in time, thereby exerting a combined therapeutic effect. For example, the additional therapeutic agent and the chimeric protein may be administered consecutively. As used herein, the term "consecutively" means that the additional therapeutic agent and the chimeric protein are administered at a time interval of more than about 60 minutes. For example, the time between the consecutive administration of the additional therapeutic agent and the chimeric protein may be more than about 60 minutes, more than about 2 hours, more than about 5 hours, more than about 10 hours, more than about 1 day, more than about 2 days, more than about 3 days, more than about 1 week apart, more than about 2 weeks apart, or more than about 1 month apart. The optimal administration time will depend on the metabolic rate, excretion rate, and / or pharmacodynamic activity of the additional therapeutic agent and the chimeric protein to be administered. Either the additional therapeutic agent or the chimeric protein may be administered first.

[0208] Co-administration also does not require that the therapeutic agents be administered to a subject by the same route of administration. Rather, each therapeutic agent may be administered by any suitable route, for example, parenterally or orally.

[0209] In some embodiments, the chimeric proteins described herein act synergistically when co-administered with another therapeutic agent. In such embodiments, the chimeric protein and the additional therapeutic agent may be administered at lower doses than those used when the agents are used in the context of monotherapy.

[0210] In some embodiments, the present invention relates to a chemotherapeutic agent as an additional therapeutic agent. For example, and without limitation, such combinations of the chimeric proteins of the present invention and chemotherapeutic agents find use in the treatment of cancer, as described elsewhere herein. Examples of chemotherapeutic agents include, but are not limited to, alkylating agents such as thiotepa and CYTOXAN cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolmelamine; acetogenins (e.g., bullatacin and bullatacinone); camptothecins (including the synthetic analog topotecan); bryostatin; calistatin; CC-1065 (including its azozelesin, carzelesin, and bizelesin synthetic analogs); cryptophycins (e.g., cryptophycin 1 and cryptophycin 8); dolastatins; duocarmycins (synthetic analogs, KW-2189 and CB including 1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin; nitrogen mustards, such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembitine, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics, such as enediyne antibiotics (e.g., calicheamicins, especially calicheamicin gamma II and calicheamicin omega II (e.g., Agnew, Chem. Intl. Ed. Engl., 33: 183-186 (1994); the dynemicins, including dynemicin A; bisphosphonates, such as clodronate; esperamicin;and neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomycin, actinomycin, ausramycin, azaserine, bleomycin, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN doxorubicin (morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin sirolimusin), epirubicin, esorubicin, idarubicin, marcelomycin, mitomycins, e.g. mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfilomycin, puromycin, queramycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites, e.g. methotrexate and 5-fluorouracil (5-FU); folic acid analogues, e.g. denopterin, methotrexate, pteropterin, trimetrexate, oxetates;purine analogues such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine;pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine;androgens such as calsterone, dromostanolone propionate, epithiostanol, mepitiostane, testolactone;antiadrenal agents such as minoglutethimide, mitotane, trilostane;folic acid supplements such as floric acid;aceglatone;aldophosph Amidoglycosides;Aminolevulinic acid;Eniluracil;Amsacrine;Bestravcil;Bisantrene;Edatraxate;Demecolcine;Diaziquone;Elformitin;Elliptinium acetate;Epothilone;Etoglucide;Gallium nitrate;Hydroxyurea;Lentinan;Lonidynin;Maytansinoids, such as maytansine and ansamitocin;Mitoguazone;Mitoxantrone;Mopidammol;Nitraerin;Pentostatin;Fenameth;Pirarubicin;Rosoxantrone;Podophyllic acid;2-Ethylhydrazide;Procarbazine;PSK polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin; schizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (e.g., T-2 toxin, veraculin A, roridin A, and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids such as TAXOL paclitaxel (Bristol-Myers Squibb Oncology, Princeton, NJ), ABRAXANE paclitaxel cremophor-free, albumin engineered nanoparticle formulation (American Pharmaceutical Partners, Schaumberg, 111), and TAXOTERE doxetaxel (Rhone-Poulenc Rorer, Anthony, France);Chlorambucil;GEMZAR gemcitabine;6-thioguanine;Mercaptopurine;Methotrexate;Platinum analogues, such as cisplatin, oxaliplatin and carboplatin;Vinblastine;Platinum;Etoposide (VP-16);Ifosfamide;Mitoxantrone;Vincristine;NAVELBINE, vinorelbine;Novantrone;Teniposide;Edatrexate;Daunomycin;Aminopterin;Xeloda;Ibandronate;Irinotecan (Camptosar, CPT-11) (Irinotecan including 5-FU and leucovorin regimens; topoisomerase inhibitors RFS2000; difluoromethylornithine (DMFO); retinoids, such as retinoic acid; capecitabine; combretastatin; leucovorin (LV); oxaliplatin, including oxaliplatin regimens (FOLFOX); lapatinib (tycarb); inhibitors of PKC-α, Raf, H-Ras, EGFR (e.g. erlotinib (Tarceva)) and VEGF-A to reduce cell proliferation, and pharma- ceutically acceptable salts, acids, or derivatives of any of the above. Additionally, the treatment may further include the use of radiation. Additionally, the treatment may further include the use of photodynamic therapy.;

[0211] In some embodiments, including without limitation infectious disease applications, the present invention relates to an anti-infective agent as an additional therapeutic agent, hi some embodiments, the anti-infective agent is an antiviral agent, including but not limited to abacavir, acyclovir, adefovir, amprenavir, atazanavir, cidofovir, darunavir, delavirdine, didanosine, docosanol, efavirenz, elvitegravir, emtricitabine, enfuvirtide, etravirine, famciclovir, and foscarnet. In some embodiments, the anti-infective agent is an antibacterial agent, including, but not limited to, cephalosporin antibiotics (cephalexin, cefuroxime, cefadroxil, cefazolin, cephalocin, cefaclor, cefamandole, cefoxitin, cefprozil, and ceftobiprole); fluoroquinolone antibiotics (cipro, levaquin, floxin, tequin, avelox, and norflox); tetracycline antibiotics (tetracycline, minocycline, oxytetracycline, and doxycycline); penicillin antibiotics (amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin, and methicillin); monobactam antibiotics (aztreonam); and carbapenem antibiotics (ertapenem, doripenem, imipenem / cilastatin, and meropenem). In some embodiments, anti-infective agents include anti-malarials (e.g., chloroquine, quinine, mefloquine, primaquine, doxycycline, artemether / lumefantrine, atovaquone / proguanil, and sulfadoxine / pyrimethamine), metronidazole, tinidazole, ivermectin, pyrantel pamoate, and albendazole.

[0212] In some embodiments, including but not limited to autoimmune applications, the additional therapeutic agent is an immunosuppressant. In some embodiments, the immunosuppressant is an anti-inflammatory agent, such as a steroidal anti-inflammatory agent or a non-steroidal anti-inflammatory agent (NSAID). Steroids, particularly adrenal corticosteroids and their synthetic analogs, are well known in the art. Examples of corticosteroids useful in the present invention include, without limitation, hydroxyltriamcinolone, alpha-methyldexamethasone, beta-methylbetamethasone, beclomethasone dipropionate, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, clobetasol valerate, desonide, desoximetasone, dexamethasone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorone acetonide, flumethasone pivalate, flucinolone acetonide, flucinonide, flucortine butyl ester, flucortolone, fluprednidene acetate, flurandrenolone, halcinonide, and the like. These include: hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenolon acetonide, medrysone, amcinafide, amcinafide, betamethasone and its esters, chloroprednisone, clocortelone, clesinolone, dichlorisone, difluprednate, flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate. The (NSAIDS) that can be used in the present invention include, but are not limited to, salicylic acid, acetylsalicylic acid, methyl salicylate, glycol salicylate, salicylmide, benzyl-2,5-diacetoxybenzoate, ibuprofen, flindac, naproxen, ketoprofen, etofenamate, phenylbutazone, and indomethacin.In some embodiments, the immunosuppressant may be a cytostatic agent, such as an alkylating agent, an antimetabolite (e.g., azathioprine, methotrexate), a cytotoxic antibiotic, an antibody (e.g., basiliximab, daclizumab, and muromonab), an anti-immunophilin (e.g., cyclosporine, tacrolimus, sirolimus), an interferon, an opioid, a TNF-binding protein, a mycophenolate, and a small molecule biological agent (e.g., fingolimod, myriocin). Additional anti-inflammatory agents are described, for example, in U.S. Patent No. 4,537,776, the entire contents of which are incorporated herein by reference.

[0213] In some embodiments, the present invention relates to combination therapy with one or more immunomodulatory agents, such as, without limitation, agents that modulate immune checkpoints. In various embodiments, the immunomodulatory agent targets one or more of PD-1, PD-L1, and PD-L2. In various embodiments, the immunomodulatory agent is a PD-1 inhibitor. In various embodiments, the immunomodulatory agent is an antibody specific for one or more of PD-1, PD-L1, and PD-L2, as described herein. For example, in some embodiments, the immunomodulatory agent is an antibody, such as, without limitation, nivolumab (ONO-4538 / BMS-936558, MDX1106, OPDIVO, BRISTOL MYERS SQUIBB), pembrolizumab (KEYTRUDA, MERCK), pidilizumab (CT-011, CURE TECH), MK-3475 (MERCK), BMS 936559 (BRISTOL MYERS SQUIBB), MPDL328OA (ROCHE). In some embodiments, the immunomodulatory agent targets one or more of CD137 or CD137L. In various embodiments, the immunomodulatory agent is an antibody specific for one or more of CD137 or CD137L. For example, in some embodiments, the immunomodulatory agent is an antibody, such as, without limitation, urelumab (also known as BMS-663513 and anti-4-1BB antibody). In some embodiments, the chimeric protein of the present invention is combined with urelumab (optionally with one or more of nivolumab, lirilumab and urelumab) for the treatment of solid tumors and / or B-cell non-Hodgkin's lymphoma and / or head and neck cancer and / or multiple myeloma. In some embodiments, the immunomodulatory agent is an agent that targets one or more of CTLA-4, AP2M1, CD80, CD86, SHP-2 and PPP2R5A. In various embodiments, the immunomodulatory agent is an antibody specific for one or more of CTLA-4, AP2M1, CD80, CD86, SHP-2 and PPP2R5A.For example, in some embodiments, the immunomodulator is an antibody, such as, without limitation, ipilimumab (MDX-010, MDX-101, Yervoy, BMS) and / or tremelimumab (Pfizer). In some embodiments, the chimeric protein of the present invention is combined with ipilimumab (optionally bavituximab) for the treatment of one or more of melanoma, prostate cancer, and lung cancer. In various embodiments, the immunomodulator targets CD20. In various embodiments, the immunomodulator is an antibody specific for CD20. For example, in some embodiments, the immunomodulator is an antibody, such as, without limitation, ofatumumab (GENMAB), obinutuzumab (GAZYVA), AME-133v (APPLIED MOLECULAR EVOLUTION), ocrelizumab (GENENTECH), TRU-015 (TRUBION / EMERGENT), veltuzumab (IMMU-106).

[0214] In some embodiments, the present invention relates to combination therapy with one or more chimeric agents described in WO 2013 / 10779, WO 2015 / 007536, WO 2015 / 007520, WO 2015 / 007542, and WO 2015 / 007903, the entire contents of which are incorporated herein by reference in their entirety.

[0215] In some embodiments, the chimeric proteins described herein include derivatives that are modified, i.e., by covalent attachment of any type of molecule to the composition, such that the covalent attachment does not prevent the activity of the composition. For example, without limitation, derivatives include compositions that are modified by, among others, glycosylation, lipidation, acetylation, PEGylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins, etc. Any of a number of chemical modifications may be performed by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin.

[0216] In yet other embodiments, the chimeric proteins described herein further comprise a cytotoxic agent, which in exemplary embodiments includes toxins, chemotherapeutic agents, radioisotopes, and agents that cause apoptosis or cell death. Such agents may be conjugated to the compositions described herein.

[0217] The chimeric proteins described herein may therefore be post-translationally modified to add effector moieties, such as chemical linkers, detectable moieties, such as fluorescent dyes, enzymes, substrates, bioluminescent agents, radioactive agents, and chemiluminescent moieties, or functional moieties, such as streptavidin, avidin, biotin, cytotoxins, cytotoxic agents, and radioactive agents.

[0218] Exemplary cytotoxic agents include, but are not limited to, methotrexate, aminopterin, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine; alkylating agents, such as mechlorethamine, thiotepa, chlorambucil, melphalan, carmustine (BSNU), mitomycin C, lomustine (CCNU), 1-methylnitrosourea, cyclophosphamide, mechlorethamine, busulfan, dibromomannitol, streptozotocin, mitomycin C, cis-dichlorodiamineplatinum(II) (DD P) Cisplatin and carboplatin (Paraplatin); anthracyclines including daunorubicin (formerly daunomycin), doxorubicin (Adriamycin), detorubicin, carminomycin, idarubicin, epirubicin, mitoxantrone and bisanthrene; antibiotics including dactinomycin (actinomycin D), bleomycin, calicheamicin, mithramycin, and anthramycin (AMC); and antimitotic agents such as the vinca alkaloids, vincristine and vinblastine. Other cytotoxic agents include paclitaxel (taxol), ricin, Pseudomonas exotoxin, gemcitabine, cytochalasin B, gramicidin D, ethidium bromide, emetine, etoposide, teniposide, colchicine, dihydroxyanthracinedione, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, procarbazine, hydroxyurea, asparaginase, corticosteroids, mitotane (O,P'-(DDD)), interferons, and mixtures of these cytotoxic agents.

[0219] Additional cytotoxic agents include, but are not limited to, chemotherapeutic agents such as carboplatin, cisplatin, paclitaxel, gemcitabine, calicheamicin, doxorubicin, 5-fluorouracil, mitomycin C, actinomycin D, cyclophosphamide, vincristine, bleomycin, VEGF antagonists, EGFR antagonists, platinum, taxol, irinotecan, 5-fluorouracil, gemcitabine, leucovorin, steroids, cyclophosphamide, melphalan, vinca alkaloids (e.g., vinblastine, vincristine, vindesine, and vinorelbine), mustard, serotonin ... and / or cyclosporine, tyrosine kinase inhibitors, radiation therapy, sex hormone antagonists, selective androgen receptor modulators, selective estrogen receptor modulators, PDGF antagonists, TNF antagonists, IL-1 antagonists, interleukins (e.g., IL-12 or IL-2), IL-12R antagonists, toxin-conjugated monoclonal antibodies, tumor antigen-specific monoclonal antibodies, erbitux, avastin, pertuzumab, anti-CD20 antibodies, rituxan, ocrelizumab, ofatumumab, DXL625, HERCEPTIN®, or any combination thereof. Toxic enzymes from plants and bacteria, such as ricin, diphtheria toxin, and Pseudomonas toxin, can be conjugated to therapeutic agents (e.g., antibodies) to generate cell-type specific killing reagents (Youle et al., Proc. Nat'l Acad. Sci. USA 77:5483(1980); Gilliland et al., Proc. Nat'l Acad. Sci. USA 77:4539(1980); Krolick et al., Proc. Nat'l Acad. Sci. USA 77:5419(1980)).

[0220] Other cytotoxic agents include cytotoxic ribonucleases as described by Goldenberg in U.S. Patent No. 6,653,104. Aspects of the present invention also relate to radioimmunoconjugates in which an alpha- or beta-particle-emitting radionuclide is stably coupled to the chimeric protein, with or without the use of a complexing agent. Such radionuclides include beta-emitters such as phosphorus-32, scandium-47, copper-67, gallium-67, yttrium-88, yttrium-90, iodine-125, iodine-131, samarium-153, lutetium-177, rhenium-186 or rhenium-188, and alpha-emitters such as astatine-211, lead-212, bismuth-212, bismuth-213 or actinium-225.

[0221] Exemplary detectable moieties further include, but are not limited to, horseradish peroxidase, acetylcholinesterase, alkaline phosphatase, beta-galactosidase, and luciferase. Additional exemplary fluorescent materials include, but are not limited to, rhodamine, fluorescein, fluorescein isothiocyanate, umbelliferone, dichlorotriazinylamine, phycoerythrin, and dansyl chloride. Additional exemplary chemiluminescent moieties include, but are not limited to, luminol. Additional exemplary bioluminescent materials include, but are not limited to, luciferin and aequorin. Additional exemplary radioactive materials include, but are not limited to, iodine-125, carbon-14, sulfur-35, tritium, and phosphorus-32.

[0222] treatment The methods and compositions described herein have application for treating a variety of diseases and disorders, including, but not limited to, cancer, infections, immune disorders, autoimmune diseases, and many other diseases and disorders.

[0223] Additionally, any of the agents of the present invention may be for use in treating, or in the manufacture of a medicament for treating, a variety of diseases and disorders, including, but not limited to, cancer, infections, immune disorders, and autoimmune diseases.

[0224] In some embodiments, the present invention relates to the treatment of patients with cancer. As used herein, cancer refers to any uncontrolled cell proliferation that may interfere with the normal function of a body organ or system, including both primary and metastatic tumors. Primary tumors or cancers that migrate from their original location and seed vital organs may eventually lead to the death of the subject through the functional deterioration of the affected organ. Metastases are cancer cells or groups of cancer cells that are separate from the primary tumor location and result from the seeding of cancer cells from the primary tumor to other parts of the body. Metastases may ultimately result in the death of the subject. For example, cancers may include benign and malignant cancers, polyps, hyperplasias, and dormant tumors or micrometastases.

[0225] Exemplary cancers that can be treated include, but are not limited to, carcinomas, such as adenocarcinoma, basal cell carcinoma, squamous cell carcinoma, and transitional cell carcinoma, sarcomas (including, for example, bone and soft tissue), leukemias (including, for example, acute myeloid, acute lymphoblastic, chronic myeloid, chronic lymphocytic, and hairy cell), lymphomas and myelomas (including, for example, Hodgkin's and non-Hodgkin's lymphoma, light chain, non-secretory, MGUS, and plasmacytoma), and central nervous system cancers, including the various subtypes, such as brain (e.g., gliomas (e.g., astrocytoma, oligodendroglioma, and ependymoma), meningiomas, pituitary adenomas, and neuromas, and spinal tumors (e.g., meningiomas and neurofibromas)).

[0226] Exemplary cancers that may be treated include, but are not limited to, basal cell carcinoma, bile duct cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colon and rectal cancer; connective tissue cancer; gastrointestinal cancer; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; gastric cancer (including gastrointestinal cancer); glioblastoma; liver cancer; liver tumors; intraepithelial neoplasia; kidney or renal cancer; laryngeal cancer; leukemia; liver cancer; lung cancer (e.g. (e.g. small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung; and squamous cell carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cancer (lips, tongue, mouth, and throat); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; respiratory tract cancer; salivary gland cancer; sarcoma; skin cancer; squamous cell carcinoma; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; urinary system cancer; vaginal cancer; Hodgkin's and non-Hodgkin's lymphomas, including B-cell lymphomas (low-grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate-grade / follicular NHL; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade lymphoblastic NHL; high-grade small noncleaved cell NHL; bulky mass disease NHL; mantle cell lymphoma; AIDS-related lymphoma); and Waldenstrom's macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); hairy cell leukemia; chronic osteoblastic leukemia; and other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal blood vessel proliferation associated with nematoses, edema (e.g., associated with brain tumors), and Meigs' syndrome.

[0227] In some embodiments, the present invention relates to the treatment of microbial and / or chronic infections or to the treatment of patients with said infections. Exemplary infections include, but are not limited to, HIV / AIDS, tuberculosis, osteomyelitis, Hepatitis B, Hepatitis C, Epstein-Barr virus or parvovirus, T-cell leukemia virus, bacterial overproliferation syndrome, fungal or parasitic infections.

[0228] In various embodiments, the compositions of the present invention are used to treat or prevent one or more inflammatory diseases or conditions, such as inflammation, acute inflammation, chronic inflammation, respiratory diseases, atherosclerosis, restenosis, asthma, allergic rhinitis, atopic dermatitis, septic shock, rheumatoid arthritis, inflammatory bowel disease, inflammatory pelvic disease, pain, ocular inflammatory diseases, celiac disease, Leigh's syndrome, glycerol kinase deficiency, familial eosinophilia (FE), autosomal recessive spastic ataxia, laryngeal inflammatory disease; tuberculosis, chronic cholecystitis, bronchiectasis, silicosis and other pneumoconiosis.

[0229] In various embodiments, the compositions of the invention are used to treat or prevent one or more autoimmune diseases or conditions, such as multiple sclerosis, diabetes, lupus, celiac disease, Crohn's disease, ulcerative colitis, Guillain-Barre syndrome, scleroderma, Goodpasture's syndrome, Wegener's granulomatosis, autoimmune epilepsy, Rasmussen's encephalitis, primary biliary sclerosis, sclerosing cholangitis, autoimmune hepatitis, Addison's disease, Hashimoto's thyroiditis, myofibromyalgia, Mayner's syndrome; transplant rejection (e.g., prevention of allograft rejection), pernicious anemia, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, Reiter's syndrome, Graves' disease, and other autoimmune diseases.

[0230] kit The present invention also provides a kit for administration of any of the agents described herein (e.g., chimeric proteins with or without various additional therapeutic agents). A kit is a collection of materials or components, including at least one of the pharmaceutical compositions of the present invention described herein. Thus, in some embodiments, the kit contains at least one of the pharmaceutical compositions described herein.

[0231] The exact nature of the components configured in the kit will depend on the intended purpose, hi one embodiment, the kit is configured for the purpose of treating a human subject.

[0232] Instructions for use may be included in the kit. Instructions for use generally include specific language describing techniques to be used in using the components of the kit to achieve a desired purpose, for example, to treat cancer. In some cases, the kit also contains other useful components, such as diluents, buffers, pharma- ceutically acceptable carriers, syringes, catheters, applicators, pipetting or measuring tools, dressings, or other useful tools that will be readily recognized by those skilled in the art.

[0233] The materials and components combined in the kit may be stored and provided to the practitioner in any convenient and suitable manner that preserves operability and usefulness. For example, the components may be provided at room temperature, refrigerated or frozen temperatures. The components are typically contained in suitable packaging materials. In various embodiments, the packaging materials are constructed by well-known methods and preferably provide a sterile, contaminant-free environment. The packaging materials may have an exterior label that indicates the contents and / or purpose of the kit and / or its components.

[0234] definition As used herein, "a," "an," or "the" may mean one or more than one.

[0235] Furthermore, the term "about," when used in connection with a reference numeral, means the reference numeral plus or minus up to 10% of the reference numeral. For example, the term "about 50" includes a range from 45 to 55.

[0236] An "effective amount," when used in connection with medical use, is an amount that is effective to provide a measurable treatment, prevention, or reduction in the incidence of a disease of interest.

[0237] As used herein, something is "reduced" if the activity and / or effect readout is reduced by a significant amount, for example, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or even up to and including at least about 100%, in the presence of an agent or stimulus compared to the absence of such modulation. As will be appreciated by those of ordinary skill in the art, in some embodiments, activity is reduced and some downstream readouts are reduced, while others may be increased.

[0238] Conversely, activity is "increased" if the activity and / or effect readout is increased a significant amount, e.g., at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or even up to and including at least about 100% or more, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, in the presence of the agent or stimulus compared to the absence of such agent or stimulus.

[0239] As referred to herein, all composition percentages are by weight of the total composition unless otherwise specified. The word "comprises" and variations thereof used herein are intended to be non-limiting, such that the recitation of items in a list is not the exclusion of other similar items that may also be useful in the compositions and methods of this technology. Similarly, the words "can" and "might" and variations thereof are intended to be non-limiting, such that the recitation of an embodiment can or may include certain elements or features does not exclude other embodiments of the present technology that do not contain these elements or features.

[0240] Although the open-ended term "comprising" as a synonym for terms such as including, containing, or having is used herein to describe and claim the invention, the invention or embodiments thereof may alternatively be described using alternative terms such as "consisting of" or "consisting essentially of."

[0241] As used herein, the words "preferred" and "preferably" refer to embodiments of the technology that provide certain benefits, under particular circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the technology.

[0242] The amount of the compositions described herein required to achieve a therapeutic effect may be determined empirically by conventional methods for a particular purpose. Generally, to administer a therapeutic agent for therapeutic purposes, the therapeutic agent is administered in a pharmacologically effective dose. A "pharmacologically effective amount", "pharmacologically effective dose", "therapeutically effective amount" or "effective amount" refers to an amount sufficient to produce a desired physiological effect or an amount capable of achieving a desired result, particularly for treating a disorder or disease. An effective amount as used herein includes, for example, an amount sufficient to delay the development of a symptom of a disorder or disease, alter the course of a symptom of a disorder or disease (e.g., delay the progression of a symptom of a disease), reduce or eliminate one or more symptoms or signs of a disorder or disease, and reverse a symptom of a disorder or disease. Therapeutic benefit also includes halting or slowing the progression of the underlying disease or condition, regardless of whether an improvement is achieved.

[0243] Effective doses, toxicity, and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine the LD50 (the dose lethal to about 50% of the population) and the ED50 (the dose therapeutically effective in about 50% of the population). Dosages can vary depending on the dosage form used and the route of administration utilized. The dose ratio between toxic and therapeutic effects is the therapeutic index, which may be expressed by the ratio LD50 / ED50. In some embodiments, compositions and methods that exhibit large therapeutic indices are preferred. Therapeutically effective doses can be estimated initially from in vitro assays, including, for example, cell culture assays. Doses can also be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 as determined in cell culture or in a suitable animal model. Levels of the described compositions in plasma can be measured, for example, by high performance liquid chromatography. The effect of any particular dosage can be monitored by a suitable bioassay. Dosages are determined by the physician and may be adjusted, if necessary, to suit the observed effects of treatment.

[0244] In certain embodiments, the effect will result in a quantifiable change of at least about 10%, at least about 20%, at least about 30%, at least about 50%, at least about 70%, or at least about 90%. In some embodiments, the effect will result in a quantifiable change of about 10%, about 20%, about 30%, about 50%, about 70%, or even about 90% or more. Therapeutic benefit also includes halting or slowing the progression of the underlying disease or disorder, regardless of whether improvement is achieved.

[0245] As used herein, "method of treatment" is equally applicable to the use of a composition to treat a disease or disorder as described herein, and / or to a composition for use and / or use in the manufacture of a medicament for treating a disease or disorder as described herein. The present invention is further illustrated by the following non-limiting examples.

[0246] Working Example In the examples below, unless stated, mutations to IFN are to human IFN-α2, SEQ ID NO:179.

[0247] The Q124R mutant represents an attenuated human IFN alpha 2 mutant that can be assayed in vivo in a murine model. Specifically, Q124R is a human IFN mutant suitable for use in mice (i.e., a human mutant IFN that functions in mice). See Nat. Comm. 2014;5:3016. doi: 10.1038 / ncomms4016, the entire contents of which are incorporated herein by reference.

[0248] The anti-human PD-1 VHH used in these examples is SEQ ID NO:23.

[0249] The anti-human PD-L1 VHH used in these examples is SEQ ID NO:158.

[0250] Example 1: Characterization of anti-mouse PD-L1 / attenuated human IFN chimeras Figure 1 shows the anti-tumor activity of the anti-PD-L1 human IFN Q124R chimeric construct compared to anti-PD-L1 VHH and PBS. In the experiment, C57BL / 6 mice were inoculated with 6x10 5 B16mCD20cl1 melanoma tumor cells (a murine melanoma cell line) were inoculated subcutaneously (50 μl). Tumors grew within ±10 mm as measured by calipers. 2 When tumor size reached 100 μl, perilesional treatment with 30 μg of various constructs (100 μl) was initiated. Figure 1 shows that anti-PD-L1 had minimal effect in the B16 tumor model, while anti-PD-L1-human IFN Q124R chimera showed antitumor activity and reduced tumor size.

[0251] The anti-PD-L1 human IFN Q124R chimera was also shown to be safe (Figure 2).In each figure, Panels A-G show: mouse weight change in the tumor study described above (Panel A), white blood cell ("wbc") and lymphocyte ("ly") counts (Panel B), neutrophil ("ne") and monocyte ("mo") counts (Panel C); red blood cell count ("rbc") and, with respect to Figure 4, hemoglobin ("hb") (Panel D); hematocrit ("hct"), mean corpuscular volume ("mcv"), mean corpuscular hemoglobin ("mch"), mean corpuscular hemoglobin concentration ("mchc") (Panel E); enucleated (pitted) red blood cells ("pit") (Panel F); and mean platelet volume ("mpv") (Panel G). Importantly, the anti-PD-L1-human IFN Q124R chimera demonstrated safety parameters far superior to those expected from wild-type interferon.

[0252] Example 2: Characterization of anti-human PD1 and PD-L1 VHHs PD-1 (programmed cell death protein 1) functions as an immune checkpoint and plays a key role in downregulating the immune system by preventing T cell activation by binding to its T cell ligands PD-L1 (programmed cell death ligand 1) and PD-L2. A plate binding assay was set up to evaluate the effect of PD-1 and PD-L1 VHHs on the interaction between these two proteins.

[0253] Specifically, maxisorp plates were coated overnight with anti-FLAG Ab (Sigma; 2 μg / ml in PBS), washed with wash buffer (PBS+0.05% Tween-20), and blocked with PBS+5% Tween-20 (2 h at room temperature). Conditioned medium containing FLAG-tagged hPD-L1 extracellular domain was incubated for 2 h at room temperature. Excess unbound protein was washed away with wash buffer. hPD1-Fc (500 ng / ml; R&D Systems; Cat. No. 1086-PD) was allowed to bind in the presence or absence of VHH for 2 h at room temperature. Bound hPD1-Fc was quantified with horseradish peroxidase (HRP)-coupled anti-human secondary AB and TMB HRP substrate (KPL).

[0254] In this experiment, hPD-1-Fc was bound to immobilized hPD-L1 in the presence of serial dilutions (1000ng / ml; 1 / 10) of VHHs specific for hPD-1, hPD-L1, mPD-L1 or an irrelevant target. The data clearly show that both hPD-1 and hPD-L1 VHHs blocked PD-1 / PD-L1 interaction, while no effect of mPD-L1 or irrelevant VHH was observed. See Figure 3.

[0255] Example 3: Anti-human PD-L1 targeting of IFN chimeras The efficiency of human PD-L1 (programmed cell death ligand 1) / attenuated IFN chimera ("AcTaferon") targeting was investigated by quantification of STAT1 phosphorylation in the human PD-L1 positive MDA-MB-321 cell line by FACS analysis.

[0256] Specifically, MDA-MB-321 cells were stimulated with anti-human PD-L1 / attenuated IFN chimeras as indicated for 15 min at 37°C in DMEM medium supplemented with 10% FBS. After stimulation, cells were fixed by adding 1 volume of Fixation Buffer I (BD Biosciences) for 10 min at 37°C and permeabilized by resuspending in 2 volumes of Perm III Buffer I (BD Biosciences) for 30 min on ice. Samples were stained with anti-STAT1 pY701 Ab (BD Biosciences) for 20 min at 4°C and analyzed with a FACSCalibur (BD Biosciences) and CellQuest Pro version 4.0.2 software (BD Biosciences).

[0257] In this experiment, MDA-MB-321 cells were stimulated with serial dilutions (100ng / ml; 1 / 5) of anti-human PD-L1 / attenuated IFN chimeras for 15 minutes at 37℃. After fixation and permeabilization, cells were stained for phospho-STAT1 and analyzed by FACS. The data clearly show that PD-L1 targeting of anti-human PD-L1 / attenuated IFN chimeras strongly increased STAT1 phosphorylation of anti-human PD-L1 / attenuated R149A IFN chimeras, but not that of anti-human PD-L1 / attenuated R33A / E120R IFN chimeras. The non-targeted (Bcll10 VHH) chimeras were unable to signal even at 100ng / ml. See Figure 4.

[0258] Example 4: Induction of signal transduction in human dendritic cells with anti-human PD-L1 VHH chimeras A dendritic cell pSTAT signaling assay was performed. The chimeras studied were anti-human PD-L1 VHH / human IFN R149A and anti-human PD-L1 VHH / human IFN R33A / E120R. Two doses of agents were studied: 100ng / ml and 500ng / ml.

[0259] Briefly, human PBMCs were isolated from blood obtained from healthy donors. Approximately 120 ml of blood was collected from each donor using heparin-coated tubes (12 tubes). Blood was kept at room temperature and processed immediately. Briefly, blood was diluted 1:1 with DPBS and 25 ml was gently layered onto 15 ml of Lympholyte H. After centrifugation, mononuclear cell rings were collected and cells were washed three times with DPBS (PBS Dulbecco's Phosphate Buffered Saline, Wisent, Cat. No. 311-425-LL) and counted. Dendritic cells were enriched from the PBMC population using the "DC Enrichment Kit" (STEMCELL Technologies, Cat. No. 19251), which contains a combination of lineage-specific monoclonal antibodies and a suspension of magnetic particles in PBS, according to the manufacturer's instructions.

[0260] Dendritic cells (DCs) were stimulated for 15 minutes in the presence or absence of test articles and controls (PBS), and the levels of phosphorylated STAT1 (pSTAT1, especially pY701-STAT1) were determined in isolated DC cell populations (Lin-(CD14 / CD16 / CD20 / CD56 / CD3) / HLA-DR+) by flow cytometry. After stimulation, cells were fixed (BD Cytofix fixation buffer, BD Biosciences, Cat. No. 554655) and then permeabilized with Perm buffer II (BD PhosFlow Perm buffer, BD Biosciences, Cat. No. 558052). Cells were then stained for phospho-STAT1 and DC surface markers (Lin- / HLA-DR+) (see table below). Both intracellular and surface staining were performed simultaneously. Flow cytometry and data acquisition were performed after washing cells with DPBS.

[0261] Table showing list of antibodies for flow cytometry staining [Table 1] Figure 5. pSTAT + Data expressed as fold change in percentage of dendritic cells are shown.

[0262] This study clearly shows that human PD-L1 antigen-targeted constructs containing an IFN signaling agent (IFN R149A) whose activity is reversible upon cell targeting promote IFN signaling in human dendritic cells (as determined by pSTAT1 induction). In contrast, no IFN signaling activation is observed with PD-L1-targeted constructs incorporating an IFN signaling agent (IFN R33A / E120R) whose activity is not reversible. Thus, as observed with comparable IFN fusion constructs targeting mouse PD-L1, targeting of IFN to human dendritic cells using a targeting moiety directed against the human PD-L1 antigen results in the induction of significant IFN signaling,

[0263] equivalent While the invention has been described in connection with specific embodiments thereof, further modifications are possible, and this application is generally intended to cover any variations, uses, or adaptations of the invention including departures from the present disclosure as applicable to the essential features hereinbefore, in accordance with the principles of the invention and as would come within known or customary practice in the art to which the invention pertains, and as set forth and in accordance with the scope of the appended claims.

[0264] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments specifically described herein which equivalents are intended to be encompassed within the scope of the following claims.

[0265] Reference All patents and publications cited herein are hereby incorporated by reference in their entirety.

[0266] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application, and nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publications by virtue of prior invention.

[0267] All headings used herein are for organizational purposes only and are not intended to limit the disclosure in any way. The content of any individual section may be equally applicable to all sections.

Claims

[Claim 1] (a) one targeting moiety that includes a recognition domain that specifically binds to Programmed Cell Death Protein 1 Ligand 1 (PD-L1); and (b) a modified signaling agent having one or more mutations that confer improved safety when compared to the wild-type signaling agent; A chimeric protein comprising: The targeting moiety and the modified signaling agent are optionally linked by one or more linkers. Chimeric proteins.